Antigen-binding molecule specifically binding to αvβ6, drug conjugate thereof, and pharmaceutical use thereof
By optimizing the antigen-binding molecule that specifically binds to αvβ6, especially the design of the amino acid sequence of the variable regions of the heavy and light chains, the problem of insufficient specificity of existing binding molecules in cancer treatment has been solved, achieving a more efficient tumor cell killing effect and lower side effects.
Patent Information
- Application Number
- PCT/CN2026/096346
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Existing antigen-binding molecules and their conjugates that specifically bind to αvβ6 have not fully met clinical needs, and more efficient and specific binding molecules are needed for cancer treatment.
An antigen-binding molecule that specifically binds to αvβ6 is provided, comprising specific heavy chain variable region and light chain variable region amino acid sequences. By optimizing the combination of HCDR and LCDR, the binding ability to αvβ6 is enhanced, and it can be used to prepare antibody-drug conjugates (ADCs) for precise killing of tumor cells.
It improved the specific binding ability to αvβ6, enhanced the killing effect of antibody-drug conjugates on tumor cells, reduced the impact on normal cells, and met the needs of clinical treatment.
Smart Images

Figure PCTCN2026096346-FTAPPB-I100001 
Figure PCTCN2026096346-FTAPPB-I100002 
Figure PCTCN2026096346-FTAPPB-I100003
Abstract
Description
Antigen-binding molecules that specifically bind to αvβ6, their drug conjugates, and their pharmaceutical uses Technical Field
[0001] This disclosure pertains to the field of biotechnology, and more specifically, it relates to antigen-binding molecules that specifically bind to αvβ6, conjugates containing such molecules, and their pharmaceutical uses. Background Technology
[0002] The statements herein are provided only as background information in connection with this disclosure and do not necessarily constitute prior art.
[0003] Integrins are a class of cell surface receptors, heterodimers formed by α and β subunits, and their family contains 24 members. Integrin activation is directly related to conformational changes, including inactive folded conformations, extended conformations, and highly activated conformations. These not only mediate cell-cell or extracellular matrix adhesion but also conduct bidirectional signal transduction, influencing various cellular behaviors such as movement, growth, survival, and differentiation. During cell or tumor cell migration and invasion, integrins bind to ligands, transforming from a folded, inactive conformation to an extended, activated conformation, mediating signal transduction, and ultimately completing these physiological activities. Therefore, integrins play a crucial role in various diseases, such as cancer, fibrotic diseases, cardiovascular diseases, autoimmune diseases, and wound healing.
[0004] Integrin αvβ6, composed of αv and β6 subunits, belongs to the RGD-binding integrins. Its extracellular domain ligands are mainly extracellular matrix proteins. αvβ6 can mediate the activation of TGF-β through binding to LAP (Latency-associated peptide), playing a role in tissue remodeling, wound repair, cell adhesion and migration, tumor metastasis, and fibrosis. αvβ6 expression levels are usually low in normal tissues, but it is upregulated in diseases such as cancer and fibrosis, especially in various epithelial-derived tumors, such as non-small cell lung cancer, head and neck cancer, esophageal cancer, pancreatic cancer, liver cancer, ovarian cancer, and cervical cancer. High expression is associated with disease progression and poor prognosis. Therefore, αvβ6 is a potential therapeutic target for cancer and has significant implications for cancer treatment (J. Niu, Z. Li / Cancer Letters 403(2017)128e137).
[0005] Antibody-drug conjugates (ADCs) are monoclonal antibodies or antibody fragments linked to biologically active drugs via linkers. They fully utilize the specificity of antibodies binding to tumor cell surface targets and the high efficiency of drugs (such as cytotoxic agents), while avoiding the drawbacks of low efficacy and excessive toxic side effects associated with antibody drugs. Compared to traditional chemotherapy drugs, antibody-drug conjugates can more precisely kill tumor cells and reduce the impact on normal cells. Therefore, the development of novel ADC drugs targeting αvβ6 holds great promise. WO2007008712A2 discloses an antigen-binding molecule that specifically binds to αvβ6, and WO2021113697A1 discloses an antigen-binding molecule that specifically binds to αvβ6 and its conjugate with MMAE. However, there is still a need for antigen-binding molecules with better specificity to αvβ6 and their conjugates to meet clinical needs. Summary of the Invention
[0006] Antigen-binding molecules that specifically bind to αvβ6
[0007] This disclosure provides an antigen-binding molecule that specifically binds to αvβ6, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:
[0008] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 92, HCDR2 contains the amino acid sequence of SEQ ID NO: 93, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7; the light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 94, LCDR2 contains the amino acid sequence of SEQ ID NO: 95, and LCDR3 contains the amino acid sequence of SEQ ID NO: 96, wherein:
[0009] X1YWIX2 SEQ ID NO: 92;
[0010] EILPGIGRTHYSEKFX3V SEQ ID NO: 93;
[0011] RSSX4SX5X6HX7X8X9ITYLN SEQ ID NO: 94;
[0012] X 10 VSX 11RFS SEQ ID NO: 95;
[0013] SQX 12 THIPYT SEQ ID NO: 96;
[0014] X1 is G or V, preferably G; X2 is E or I, preferably E;
[0015] X3 can be K or Q, with K being preferred;
[0016] X4 is Q or E, preferably Q; X5 is L or V, preferably L; X6 is V or A, preferably V; X7 is S or T, preferably S; X8 is N, Q or T, preferably N; X9 is G, V or E, preferably G.
[0017] X 10 The choice is K or R, with K being preferred; X 11 It can be N or S, with N being preferred;
[0018] X 12 It can be S or T, with S being preferred.
[0019] This disclosure provides an antigen-binding molecule that specifically binds to αvβ6, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:
[0020] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, 24-32, 63, 64, 66, or 67, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80, 33-41, 68-79, 81, 82, or 83; or
[0021] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 4.
[0022] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0023] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, 24, 30, or 63, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80, 33, 38, 79, or 83; or
[0024] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 4.
[0025] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0026] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65 or 30, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80 or 38; or
[0027] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 4.
[0028] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0029] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80.
[0030] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0031] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 30, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 38.
[0032] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0033] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 38.
[0034] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0035] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 30, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80.
[0036] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0037] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 4.
[0038] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, wherein the HCDR1, HCDR2, and HCDR3 of the heavy chain variable regions and the LCDR1, LCDR2, and LCDR3 of the light chain variable regions are defined according to a numbering rule selected from Kabat, IMGT, Chothia, AbM, and Contact. In some embodiments, the HCDR1, HCDR2, and HCDR3 of the heavy chain variable regions and the LCDR1, LCDR2, and LCDR3 of the light chain variable regions are defined according to the Kabat numbering rule. In some embodiments, the HCDR1, HCDR2, and HCDR3 of the heavy chain variable regions and the LCDR1, LCDR2, and LCDR3 of the light chain variable regions are defined according to the IMGT numbering rule. In some embodiments, the HCDR1, HCDR2, and HCDR3 of the heavy chain variable regions and the LCDR1, LCDR2, and LCDR3 of the light chain variable regions are defined according to the Chothia numbering rule. In some embodiments, the heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3, are defined according to the AbM numbering rules. In some embodiments, the heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3, are defined according to the Contact numbering rules.
[0039] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0040] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 5, 97, 102, 46, or 47; HCDR2 contains the amino acid sequence of SEQ ID NO: 6, 98, 103, or 23; and HCDR3 contains the amino acid sequence of SEQ ID NO: 7 or 99. The light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 8, 100, 19, 20, 54, 55, 56, 57, 58, or 59; LCDR2 contains the amino acid sequence of SEQ ID NO: 21, 106, 9, 101, or 22; and LCDR3 contains the amino acid sequence of SEQ ID NO: 10 or 62. This includes amino acids as defined according to the Kabat, IMGT, and Chothia numbering rules.
[0041] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0042] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 5, 97, 102, or 46; HCDR2 contains the amino acid sequence of SEQ ID NO: 6, 98, or 103; and HCDR3 contains the amino acid sequence of SEQ ID NO: 7 or 99. The light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 8, 100, or 57; LCDR2 contains the amino acid sequence of SEQ ID NO: 21, 106, 101, or 9; and LCDR3 contains the amino acid sequence of SEQ ID NO: 10 or 62. This includes amino acids as defined according to the Kabat, IMGT, and Chothia numbering rules.
[0043] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0044] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 5, HCDR2 contains the amino acid sequence of SEQ ID NO: 6, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7, and the light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 8, LCDR2 contains the amino acid sequence of SEQ ID NO: 21, and LCDR3 contains the amino acid sequence of SEQ ID NO: 10.
[0045] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0046] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 97, HCDR2 contain the amino acid sequence of SEQ ID NO: 98, and HCDR3 contain the amino acid sequence of SEQ ID NO: 99. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 100, LCDR2 contain the amino acid sequence of SEQ ID NO: 106, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to the IMGT numbering rules.
[0047] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0048] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 102, HCDR2 contain the amino acid sequence of SEQ ID NO: 103, and HCDR3 contain the amino acid sequence of SEQ ID NO: 7. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 8, LCDR2 contain the amino acid sequence of SEQ ID NO: 21, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to Chothia numbering rules.
[0049] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0050] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 5, HCDR2 contains the amino acid sequence of SEQ ID NO: 6, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7, and the light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 8, LCDR2 contains the amino acid sequence of SEQ ID NO: 9, and LCDR3 contains the amino acid sequence of SEQ ID NO: 10.
[0051] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0052] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 97, HCDR2 contain the amino acid sequence of SEQ ID NO: 98, and HCDR3 contain the amino acid sequence of SEQ ID NO: 99. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 100, LCDR2 contain the amino acid sequence of SEQ ID NO: 101, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to the IMGT numbering rules.
[0053] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0054] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 102, HCDR2 contain the amino acid sequence of SEQ ID NO: 103, and HCDR3 contain the amino acid sequence of SEQ ID NO: 7. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 8, LCDR2 contain the amino acid sequence of SEQ ID NO: 9, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to the Chothia numbering rules.
[0055] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0056] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 5, HCDR2 contains the amino acid sequence of SEQ ID NO: 6, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7, and the light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 8, LCDR2 contains the amino acid sequence of SEQ ID NO: 21, and LCDR3 contains the amino acid sequence of SEQ ID NO: 62.
[0057] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0058] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 5, HCDR2 contains the amino acid sequence of SEQ ID NO: 6, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7. The light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 57, LCDR2 contains the amino acid sequence of SEQ ID NO: 21, and LCDR3 contains the amino acid sequence of SEQ ID NO: 10.
[0059] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0060] The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 46, HCDR2 contains the amino acid sequence of SEQ ID NO: 6, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7, and the light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 8, LCDR2 contains the amino acid sequence of SEQ ID NO: 21, and LCDR3 contains the amino acid sequence of SEQ ID NO: 10.
[0061] Unless otherwise specified, the HCDR1, HCDR2, and HCDR3 of the heavy chain variable regions and the LCDR1, LCDR2, and LCDR3 of the light chain variable regions are defined according to the Kabat numbering rules.
[0062] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments is an antibody. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 is a monoclonal antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, or a fusion protein. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 is a monoclonal antibody. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 is a monospecific antibody. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 is a humanized antibody. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments includes a frame region (FR) of a human antibody.
[0063] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, wherein the heavy chain variable region has FR1, FR2, FR3 derived from IGHV1-3*01 or IGHV1-46*01 and FR4 derived from IGHJ6*01 or IGHJ4*01, and is unsubstituted or contains fragments selected from 24T, 28I, 38K, 40R, 44G, 66K, 69F, 71A, 75S, 76N, 78A, 83T One or more amino acid substitutions from the group consisting of 2V, 45K, 89I and / or 1E; and / or the light chain variable region having FR1, FR2, FR3 derived from IGKV2-40*01, IGKV2-28*01 or IGKV2D-29*02, and FR4 fragment derived from IGKJ4*01 or IGKJ2*01, and which is unsubstituted or contains one or more amino acid substitutions selected from the group consisting of 2V, 45K, 87F and / or 101E.
[0064] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, and the heavy chain variable region is unsubstituted or comprises one or more amino acid substitutions selected from the group consisting of 31V, 35I, 69Y, 71G and / or 74Q; and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38, and the light chain variable region is unsubstituted or comprises one or more amino acid substitutions selected from the group consisting of 3A, 7S, 9V, 27E, 27bV, 27cA, 27eT, 28T, 29E, 85T, 87Y and / or 91T. In some embodiments, the above-mentioned variable regions are defined according to the Kabat numbering rules.
[0065] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, wherein the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 5, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the FR of the heavy chain variable region is unsubstituted or comprises one or more amino acid substitutions selected from the group consisting of 69Y, 71G, 74Q, 24T, 28I, 38K, 40R, 44G, 66K, 69F, 71A, 75S, 76N, 78A, 83T, 85D, 89I and / or 1E; and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 7. The amino acid sequence of NO: 10, and the FR of the light chain variable region is either unsubstituted or contains one or more amino acid substitutions selected from the group consisting of 3A, 7S, 9V, 85T, 87Y, 2V, 45K, 87F and / or 101E. In some embodiments, the above-mentioned variable region and CDR are defined according to the Kabat numbering rules.
[0066] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0067] The heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 65, 24-32, 63, 64, 66, or 67, or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 65, 24-32, 63, 64, 66, or 67, and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 80, 33-41, 68-79, 81, 82, or 83 ... the light chain variable region comprises an NO: 80, 33-41, 68-79, 81, 82 or 83 have amino acid sequences with at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity.
[0068] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0069] The heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 65, 24, 30 or 63 or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with SEQ ID NO: 65, 24, 30 or 63, and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 80, 33, 38, 79 or 83 or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with SEQ ID NO: 80, 33, 38, 79 or 83.
[0070] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0071] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 4.
[0072] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0073] The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 65, 24-32, 63, 64, 66 or 67, and the light chain variable region contains the amino acid sequence of SEQ ID NO: 80, 33-41, 68-79, 81, 82 or 83.
[0074] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0075] The heavy chain variable region contains an amino acid sequence of SEQ ID NO: 65, 24, 30 or 63, and the light chain variable region contains an amino acid sequence of SEQ ID NO: 80, 33, 38, 79 or 83.
[0076] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0077] The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 65 or 30, and the light chain variable region contains the amino acid sequence of SEQ ID NO: 80 or 38.
[0078] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0079] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or
[0080] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or
[0081] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 79; or
[0082] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 83; or
[0083] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33; or
[0084] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or
[0085] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or
[0086] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or
[0087] The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 3, and the light chain variable region contains the amino acid sequence of SEQ ID NO: 4.
[0088] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein the antigen-binding molecule that specifically binds to αvβ6 is humanized, reversed mutation, affinity maturation, reduced hydrophobicity, removed T cell epitopes, reduced antibody deamidation, and / or reduced antibody isomerization.
[0089] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, is an antigen-binding fragment. In some embodiments, the antigen-binding fragment is an antibody fragment. In some embodiments, the antigen-binding fragment is selected from Fab, Fab′, F(ab′)2, Fv, scFv, and dsFv.
[0090] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments comprises a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is derived from the heavy chain constant regions of human IgG1, IgG2, IgG3, and IgG4, and the light chain constant region is derived from the light chain constant regions of human κ and λ chains. In some embodiments, the heavy chain constant region is derived from the heavy chain constant region of human IgG1, and the light chain constant region is derived from the light chain constant region of human κ.
[0091] In some embodiments, the human IgG1 heavy chain constant region contains one or more mutations selected from F234A and L235A, and the light chain constant region is the human κ light chain constant region.
[0092] In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 11 or 89, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 12. In some embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 89, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 12.
[0093] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0094] The heavy chain comprises an amino acid sequence of SEQ ID NO: 91, 42, 44, 84, 85, or 90, or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 91, 42, 44, 84, 85, or 90, and the light chain comprises an amino acid sequence of 86, 43, 45, 87, or 88, or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 86, 43, 45, 87, or 88; or
[0095] The heavy chain comprises the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 13, and the light chain comprises the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO: 14.
[0096] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0097] The heavy chain comprises the amino acid sequence of SEQ ID NO: 91, 42, 44, 84, 85 or 90, and the light chain comprises the amino acid sequence of SEQ ID NO: 86, 43, 45, 87 or 88.
[0098] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0099] The heavy chain contains the amino acid sequence of SEQ ID NO: 13, and the light chain contains the amino acid sequence of SEQ ID NO: 14.
[0100] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0101] The heavy chain comprises the amino acid sequence of SEQ ID NO: 91, and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or
[0102] The heavy chain comprises the amino acid sequence of SEQ ID NO: 44, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0103] The heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 87; or
[0104] The heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or
[0105] The heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 88; or
[0106] The heavy chain comprises the amino acid sequence of SEQ ID NO: 90, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0107] The heavy chain comprises the amino acid sequence of SEQ ID NO: 42, and the light chain comprises the amino acid sequence of SEQ ID NO: 43; or
[0108] The heavy chain comprises the amino acid sequence of SEQ ID NO: 84, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0109] The heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0110] The heavy chain contains the amino acid sequence of SEQ ID NO: 13, and the light chain contains the amino acid sequence of SEQ ID NO: 14.
[0111] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0112] The heavy chain comprises the amino acid sequence of SEQ ID NO: 91, and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or
[0113] The heavy chain comprises the amino acid sequence of SEQ ID NO: 44, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0114] The heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or
[0115] The heavy chain comprises the amino acid sequence of SEQ ID NO: 90, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0116] The heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or
[0117] The heavy chain contains the amino acid sequence of SEQ ID NO: 44, and the light chain contains the amino acid sequence of SEQ ID NO: 86.
[0118] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0119] The heavy chain contains the amino acid sequence of SEQ ID NO: 91, and the light chain contains the amino acid sequence of SEQ ID NO: 86.
[0120] On the other hand, this disclosure provides an antigen-binding molecule that specifically binds to αvβ6, which competes with the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims for binding to human αvβ6.
[0121] On the other hand, this disclosure provides an antigen-binding molecule that specifically binds to αvβ6, which, together with the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, binds to the same human αvβ6 antigenic epitope.
[0122] On the other hand, this disclosure provides an isolated nucleic acid that encodes an antigen-binding molecule that specifically binds to αvβ6 as described in the previous one.
[0123] On the other hand, this disclosure provides a carrier containing the isolated nucleic acid as described above.
[0124] On the other hand, this disclosure provides a host cell containing the isolated nucleic acid as described above, or the vector as described above.
[0125] On the other hand, this disclosure provides a method for producing an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, the method comprising culturing host cells as described in the preceding claims in a culture medium to form and accumulate the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, and recovering the antigen-binding molecule from the culture.
[0126] Coupled
[0127] This disclosure provides a conjugate comprising an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims and a payload, wherein the payload is coupled to the antigen-binding molecule that specifically binds to αvβ6.
[0128] In some embodiments, as described above, the conjugate, wherein the payload is selected from cytotoxic drugs, antitumor agents, immunomodulators, bioresponse modifiers, lectins, chromophores, fluorophores, chemiluminescent compounds, enzymes, metal ions, and any combination thereof.
[0129] In some implementations, as described above, the conjugate is eribulin or a derivative thereof.
[0130] On the other hand, this disclosure provides a coupling having a structure as shown under the general formula Ab-LD:
[0131] in:
[0132] Ab is an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, preferably an anti-αvβ6 antibody;
[0133] n is 1 to 20, where n is a decimal or an integer; preferably n is 1 to 10, where n is a decimal or an integer; more preferably n is 1 to 8, where n is a decimal or an integer; most preferably n is 3 to 8, where n is a decimal or an integer.
[0134] -L- is -L 1 -L 2 -L 3 -L 4 - The connector unit shown, wherein:
[0135] L 1 -(succinimide-3-yl-N)-W 1 -(O-CR 1 R 2 -CR 3 R 4 -) q -C(O)-, where R 1 R 2 R 3 and R 4 It is a hydrogen atom or a carbon atom. 1-6 Alkyl group; q is 0, 1, 2, 3, 4, 5 or 6;
[0136] L 2 It is a chemical bond;
[0137] L 3The peptide residues are selected from peptide residues consisting of 1 to 4 amino acid residues (i.e., monopeptide residues, dipeptide residues, tripeptide residues, and tetrapeptide residues), wherein the amino acid residues are selected from amino acids formed from phenylalanine, alanine, glycine, cysteine, valine, lysine, citrulline, serine, glutamine, glutamic acid, aspartic acid, and asparagine; preferably, L 3 Selected from dipeptide residues represented by VA, valine-citrulline, and tetrapeptide residues represented by GGFG (SEQ ID NO: 109); more preferably, L 3 The dipeptide residues represented by valine-citrulline;
[0138] L 4 Selected from chemical bonds, -NR 5 -W 1 -and-NR 5 -W 2 -W 1 -OC(O)-;
[0139] R 5 It is a hydrogen atom or a carbon atom. 1-6 alkyl;
[0140] W 1 -(CR) 6 R 7 ) p -, R 6 and R 7 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Haloalkyl, p is 1, 2, 3, 4, 5 or 6;
[0141] W 2 For phenyl, Substituted phenyl or Substituted phenyl;
[0142] The L of -L- 1 The terminal is connected to Ab, L 4 The end is connected to the drug.
[0143] In some implementations, as described above, the coupling agent, wherein
[0144] L 1 -(succinimide-3-yl-N)-W 1 -(O-CH2-CH2-) q -C(O)-, where q is 0, 1, 2, 3, 4, 5 or 6;
[0145] L 2 It is a chemical bond;
[0146] L3 It consists of dipeptide residues containing valine-citrulline;
[0147] L 4 It is -N(CH3)CH2-, -NHCH2-, or -NH-phenyl-CH2-OC(O)-;
[0148] The L of -L- 1 The terminal is connected to Ab, L 4 The end is connected to the drug.
[0149] In some embodiments, the couplings described above have a structure as shown under the general formula Ab-L-D':
[0150] Wherein, the Ab is an antigen-binding molecule that specifically binds to αvβ6 as described in the preceding claim, wherein the L and n are as described in the preceding claim.
[0151] In some implementations, the coupling as described above has the following structure:
[0152] in,
[0153] n can be 1 to 8, where n is a decimal or an integer; preferably, n can be 3 to 8, where n is a decimal or an integer.
[0154] Ab is an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 5, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10.
[0155] In some embodiments, as described above, the conjugate, wherein the Ab is an antigen-binding molecule that specifically binds to αvβ6, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or
[0156] The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 30, and the light chain variable region contains the amino acid sequence of SEQ ID NO: 38.
[0157] In some embodiments, as described above, the conjugate is an anti-αvβ6 antibody comprising a heavy chain and a light chain, wherein:
[0158] The heavy chain comprises the amino acid sequence of SEQ ID NO: 91, and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or
[0159] The heavy chain contains the amino acid sequence of SEQ ID NO: 90, and the light chain contains the amino acid sequence of SEQ ID NO: 45.
[0160] In some implementations, the coupling as described above has the following structure:
[0161] Wherein, Ab is an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, and n is as defined in the general formula Ab-LD.
[0162] In some embodiments, the conjugate or a pharmaceutically acceptable salt thereof, as described in any of the preceding embodiments, wherein n refers to the average amount of drug carried by each conjugate molecule in the conjugate population, or may be expressed as the ratio of drug to ligand; preferably, the conjugate is an antibody-drug conjugate.
[0163] In some embodiments, the conjugate or its pharmaceutically acceptable salt as described in any of the preceding claims, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or any two values; preferably, n is 1-10; more preferably, n is 1-8, or 2-8, or 2-7, or 2-6, or 2-5, or 2-4, or 3-8, or 3-7, or 3-6, or 4-8, or 4-7, or 4-6, or 4-5.
[0164] In some embodiments, the conjugate or its pharmaceutically acceptable salt as described in any of the preceding embodiments is used, wherein n is 1 to 10; preferably, n is 1 to 8; more preferably, n is 3 to 8.
[0165] On the other hand, this disclosure provides a pharmaceutical composition comprising an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[0166] On the other hand, this disclosure provides a pharmaceutical composition comprising a conjugate as described in any of the preceding claims, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[0167] In some embodiments, based on the total weight of the composition, the pharmaceutical composition contains 0.01% to 99.99% of the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, or the conjugate as described in any of the preceding embodiments. In some embodiments, the pharmaceutical composition contains 0.1% to 99.9% of the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, or the conjugate as described in any of the preceding embodiments. In some embodiments, the pharmaceutical composition contains 0.5% to 99.5% of the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, or the conjugate as described in any of the preceding embodiments. In some embodiments, the pharmaceutical composition contains 1% to 99% of the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, or the conjugate as described in any of the preceding embodiments. In some embodiments, the pharmaceutical composition contains 2% to 98% of the antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding embodiments, or the conjugate as described in any of the preceding embodiments.
[0168] In some embodiments, the pharmaceutical composition contains 0.01% to 99.99% pharmaceutically acceptable carriers, diluents, or excipients based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1% to 99.9% pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical composition contains 0.5% to 99.5% pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical composition contains 1% to 99% pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical composition contains 2% to 98% pharmaceutically acceptable carriers, diluents, or excipients.
[0169] On the other hand, this disclosure provides the use of an antigen-binding molecule that specifically binds to αvβ6 as described in any of the preceding claims, or a conjugate as described in any of the preceding claims, or a pharmaceutical composition as described in any of the preceding claims, in the preparation of a medicament for the prevention or treatment of a disease or condition.
[0170] On the other hand, this disclosure provides a method for preventing or treating a disease or condition, the method comprising administering to a subject an antigen-binding molecule that specifically binds to αvβ6 as described in the preceding claim, or a conjugate as described in the preceding claim, or a pharmaceutical composition as described in the preceding claim.
[0171] On the other hand, this disclosure provides an antigen-binding molecule that specifically binds to αvβ6 as described in the preceding claim, or a conjugate as described in the preceding claim, or a pharmaceutical composition as described in the preceding claim, for use as a medicament. In some embodiments, the medicament is used to prevent or treat a disease or condition.
[0172] In some implementations, the disease or condition described in the preceding one is a tumor or cancer.
[0173] In some implementations, the tumor or cancer described in any of the preceding embodiments is selected from adenocarcinoma, squamous cell carcinoma, bladder cancer, lung cancer (non-small cell lung cancer and small cell lung cancer), gastric cancer; esophageal cancer, pancreatic cancer, head and neck cancer, ovarian cancer, gastroesophageal junction cancer, and cervical cancer.
[0174] In some implementations, the tumor or cancer, as described in the preceding one, is selected from lung cancer, head and neck cancer, or esophageal cancer.
[0175] In some implementations, the antigen-binding molecules that specifically bind to αvβ6 provided in this disclosure have good endocytic activity and weak LAP blocking activity. Attached Figure Description
[0176] Figure 1. Detection of endocytosis of Hu37H7L6-AA and hu37H7-3L6-13-AA antibodies into cells. Detailed Implementation
[0177] the term
[0178] To facilitate understanding of this disclosure, certain technical and scientific terms are described below. Unless otherwise expressly defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
[0179] The singular forms “a,” “an,” and “the” used in the specification and claims include plural references unless the context clearly indicates otherwise.
[0180] Unless the context clearly requires otherwise, the words “comprising,” “having,” “including,” etc., in the patent specification and claims should be understood as “including but not limited to,” rather than as exclusive or exhaustive.
[0181] The term "and / or" implies both "and" and "or". For example, the phrase "A, B and / or C" is intended to cover each of the following: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0182] The three-letter and single-letter codes for amino acids used in this disclosure are as described in J. Biol. Chem., 243, p3558 (1968).
[0183] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are subsequently modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs are compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., the α-carbon bound to hydrogen, carboxyl, amino, and R groups), such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. These analogs have modified R groups (e.g., ortholeucine) or modified peptide backbones but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimics are chemical compounds that have a structure different from the general chemical structure of amino acids but function in a manner similar to naturally occurring amino acids.
[0184] The term "amino acid mutation" includes amino acid substitution (also known as amino acid replacement), deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be performed to achieve the final construct, provided that the final construct possesses the desired properties, such as reduced or absent binding to Fc receptors. Amino acid sequence deletions and insertions include deletions and insertions at the amino and / or carboxyl ends of the polypeptide chain. A specific amino acid mutation can be an amino acid substitution. In some embodiments, an amino acid mutation is a non-conservative amino acid substitution, i.e., replacing one amino acid with another amino acid that has a different structure and / or chemical properties. Amino acid substitution includes substitution by non-naturally occurring amino acids or by derivatives of 20 naturally occurring amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. Methods other than genetic engineering that alter amino acid side chain groups, such as chemical modification, are also expected to be available. Various names may be used herein to refer to the same amino acid mutation. In this document, the amino acid residue at a specific site may be represented by the format "position + amino acid residue," for example, 234A, indicating that the amino acid residue at position 234 is A. It should be understood that when the amino acid sequence is defined in the claims using the format "position + residue," the amino acid before the mutation at that site does not constitute a limitation on the technical solution. In this document, "the Fc region contains amino acid mutations of 234A and 235A" means that the amino acid mutation in the Fc region includes a mutation at position 234 to alanine (A) and a mutation at position 235 to alanine (A).
[0185] The terms “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers, where one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acids, as well as to both naturally occurring and non-naturally occurring amino acid polymers. Unless otherwise stated, a particular peptide sequence also implicitly encompasses variants with conserved modifications.
[0186] The term "oligonucleotide" refers to oligonucleotide compounds that are typically less than about 200 nucleotides in length. Examples of oligonucleotides include, but are not limited to, RNA interference (RNAi) oligonucleotides (e.g., antisense oligonucleotides (ASO), siRNAs, shRNAs, dsRNAs, etc.), microRNAs (miRNAs), spacer polymers, mixers, phosphorodiamidate morpholinos, peptide nucleic acids, aptamers, and guide nucleic acids (e.g., Cas9 guide RNAs). Oligonucleotides can be single-stranded or double-stranded. Oligonucleotides can be sense or antisense oligonucleotides.
[0187] The term "antigen-binding molecule" is used in the broadest sense to encompass a variety of molecules that specifically bind antigens, including but not limited to antibodies, other peptides with antigen-binding activity, and antibody fusion proteins formed by the fusion of the two, as well as any molecule containing the aforementioned antibodies, peptides, or antibody fusion proteins, provided they exhibit the desired antigen-binding activity. Exemplarily, the antigen-binding molecules described herein are monoclonal antibodies, monospecific antibodies, polyclonal antibodies, and multispecific antibodies.
[0188] The term “antibody” is used in the broadest sense and covers a wide range of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, antibody fragments, and antigen-binding fragments (or antigen-binding portions), as long as they exhibit the desired antigen-binding activity.
[0189] The term "antigen-binding fragment" encompasses full-length antibodies, Fab, modified Fab, Fab', Fab'-SH, modified Fab', F(ab')2, Fv, dsFv, Fab-Fv, Fab-dsFv, Fd, single-domain antibodies (sdAb, e.g., VH, VL, or VHH), single-chain Fab (scFab), single-chain antibodies (e.g., scFv, sc(Fv)2), biantibodies, linear antibodies, bivalent, trivalent, or tetravalent antibodies, Bis-scFv, diabetic, tribody, triabody, tetrabody, and epitope-binding fragments of any of the above. Methods for generating and preparing these antigen-binding fragments are well known in the art.
[0190] The term "antibody fragment" refers to a molecule that is distinct from the intact antibody but contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, dsFv, Fab, Fab′, Fab′-SH, F(ab′)2, Fd, single-domain antibodies (sdAb, such as VH, VL, or VHH), single-chain Fab (scFab), biantibodies, linear antibodies, single-chain antibodies (such as scFv, sc(Fv)2); and multispecific antibodies formed from antibody fragments.
[0191] The term "natural antibody" refers to naturally occurring immunoglobulin molecules. For example, natural IgG antibodies are heterotetraglycoproteins of approximately 150,000 Daltons, composed of two light chains and two heavy chains linked by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or heavy chain variable region, followed by a heavy chain constant region. The natural IgG heavy chain constant region typically contains three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called a variable light domain or light chain variable domain, followed by a constant light domain (light chain constant region, CL).
[0192] The terms "full-length antibody," "intact antibody," and "complete antibody" are used interchangeably in this document, referring to antibodies with a structure substantially similar to that of natural antibodies or with a heavy chain containing the Fc region as defined herein. The light chain of a natural intact antibody includes a variable region (VL) and a constant region (CL), with VL located at the amino terminus of the light chain. The constant region includes the κ and λ chains. The heavy chain includes a variable region (VH) and constant regions (CH1, CH2, and CH3), with VH located at the amino terminus of the heavy chain and the constant region located at the carboxyl terminus. CH3 is closest to the carboxyl terminus of the polypeptide. The heavy chain can belong to any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE.
[0193] The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of an antibody heavy chain, including both native and modified Fc regions. In some embodiments, the Fc region comprises two identical or different subunits. In some embodiments, the Fc region of a human IgG heavy chain is defined as an amino acid residue extending from the Cys226 position or from Pro230 to its carboxyl terminus. Suitable Fc regions for the antibodies described herein include the Fc regions of human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. In some embodiments, the boundaries of the Fc region may also vary, for example, by omitting the C-terminal lysine (residue 447 according to the EU numbering system) or omitting both the C-terminal glycine and lysine (residues 446 and 447 according to the EU numbering system). Unless otherwise stated, the Fc region is numbered according to the EU numbering system, also known as the EU index.
[0194] The Fc region can be appropriately obtained by partially digesting IgG monoclonal antibodies with proteolytic enzymes such as pepsin, followed by eluting the components adsorbed on the protein A or protein G column. As the proteolytic enzyme, any enzyme capable of restrictively digesting full-length antibodies to produce Fab and F(ab')2 by appropriately setting the enzyme reaction conditions such as pH is acceptable; there is no particular limitation, and examples include pepsin and papain.
[0195] The term "variable region" or "variable domain" in an antibody refers to the domain in the antibody heavy or light chain involved in antibody binding to the antigen. In this paper, the antibody heavy chain variable region (VH) and light chain variable region (VL) each contain four conserved frame regions (FRs) and three complementarity-determining regions (CDRs). The term "complementarity-determining region" or "CDR" refers to the region within the variable domain that primarily facilitates antigen binding; "frame" or "FR" refers to the variable domain residues other than the CDR residues. The VH contains three CDR regions: HCDR1, HCDR2, and HCDR3; the VL contains three CDR regions: LCDR1, LCDR2, and LCDR3. Each VH and VL consists of three CDRs and four FRs arranged in the following order from the amino terminus (also called the N-terminus) to the carboxyl terminus (also called the C-terminus): FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0196] The amino acid sequence boundaries of CDRs can be determined using various well-known schemes, such as the "Kabat" numbering rule, the "Chothia" numbering rule, the "ABM" numbering rule, the "contact" numbering rule, and the ImMunoGenTics (IMGT) numbering rule. The correspondence between various numbering systems is well known to those skilled in the art and is exemplified as shown in Table A below.
[0197] Table A. Relationships between CDR numbering systems
[0198] Unless otherwise stated, the variable areas and CDRs in this disclosure embodiment are subject to the "Kabat" numbering rule.
[0199] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a specific source or species, while the remaining portion of the heavy and / or light chain is derived from another different source or species.
[0200] The term "humanized" antibody refers to an antibody that retains the reactivity of a non-human antibody while exhibiting lower immunogenicity in humans. For example, this can be achieved by retaining the non-human CDR region and replacing the rest of the antibody with its human counterpart (i.e., the frame region portion of the constant region and the variable region).
[0201] The terms "human antibody," "humanized antibody," "fully human antibody," and "completely human antibody" are used interchangeably, referring to antibodies whose variable and constant regions are human sequences. This term encompasses antibodies derived from human genes but with sequence alterations, such as reduced potential immunogenicity, increased affinity, or the elimination of cysteine or glycosylation sites that might cause undesirable folding. This term also covers antibodies recombined in non-human cells (which may confer glycosylations not characteristic of human cells). The term also includes antibodies produced in transgenic mice containing some or all human immunoglobulin heavy and light chain loci. The term "human antibody" explicitly excludes humanized antibodies.
[0202] The term "affinity" refers to the overall strength of the non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and its binding ligand (e.g., an antigen). Unless otherwise specified, as used herein, binding "affinity" refers to internal binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its ligand Y can typically be represented by the dissociation constant (KD). Affinity can be measured using conventional methods known in the art, including those described herein.
[0203] As used herein, the term "kassoc" or "ka" refers to the association rate of a specific antibody-antigen interaction, and the term "kdis" or "kd" refers to the dissociation rate of a specific antibody-antigen interaction. The term "KD" refers to the dissociation constant, which is derived from the ratio of kd to ka (i.e., kd / ka) and expressed as a molar concentration (M). The KD value of an antibody can be determined using methods known in the art. For example, it can be measured using a biosensing system such as a system for measuring surface plasmon resonance (e.g., Biacore), or by measuring affinity in solution using solution equilibrium titration (SET).
[0204] The term "surface plasmon resonance" refers to the optical phenomenon of analyzing real-time interactions by detecting changes in protein concentration within a biosensor matrix, for example, using the BIAcore system (Biacore LifeSciences division of GE Healthcare, Piscataway, NJ).
[0205] The term "effector function" refers to biological activities attributable to the antibody's Fc region (either the native Fc region or the Fc region with amino acid sequence mutations) and that vary across antibody isotypes. Examples of antibody effector functions include, but are not limited to: C1q binding and complement-dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0206] The term "monoclonal antibody" refers to a group of antibodies that are essentially homogeneous, meaning that the antibody molecules contained in this group have the same amino acid sequence, except for the possible small number of naturally occurring mutations. In contrast, polyclonal antibodies typically comprise a variety of different antibodies with varying amino acid sequences in their variable domains, and they generally target different epitopes specifically. "Monoclonal" should not be interpreted as requiring the production of the antibody through any particular method.
[0207] The term "bispecific antibody" refers to an antibody (including the antibody or its antigen-binding fragment, such as a single-chain antibody) capable of specifically binding to two different antigens or at least two different antigenic epitopes of the same antigen. Various structures of bispecific antibodies have been disclosed in the prior art. Based on the integrity of the IgG molecule, they can be classified into IgG-like bispecific antibodies and antibody fragment-based bispecific antibodies. Based on the number of antigen-binding regions, they can be classified into bivalent, trivalent, tetravalent, or more bispecific antibodies. Based on structural symmetry, they can be classified into symmetrical and asymmetrical bispecific antibodies. Among these, bispecific antibodies based on antibody fragments, such as Fab fragments lacking the Fc fragment, form bispecific antibodies by combining two or more Fab fragments into one molecule. They exhibit lower immunogenicity, smaller molecular weight, and higher tumor tissue penetration. IgG-like bispecific antibodies (e.g., those with an Fc fragment) have a relatively larger molecular weight. The Fc fragment facilitates antibody purification and improves its solubility and stability. The Fc portion may also bind to the receptor FcRn, increasing the antibody's serum half-life.
[0208] The term "antigen" refers to a molecule or molecular part that can be selectively bound by antigen-binding proteins, including, for example, antibodies. An antigen may have one or more epitopes that can interact with different antigen-binding proteins, such as antibodies.
[0209] The term "epitope" refers to a region on an antigen that is capable of specifically binding to an antibody or its antigen-binding fragment. Epitopes can be formed from a continuous string of amino acids (linear epitopes) or contain non-continuous amino acids (conformal epitopes), such as those spatially close due to antigen folding. The difference between conformational and linear epitopes is that antibody binding to a conformational epitope is lost in the presence of a denaturing solvent. An epitope contains at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation. Screening for antibodies that bind to a specific epitope (i.e., those that bind the same epitope) can be performed using methods routine in the art, such as, but not limited to, alanine scanning, Western blotting, peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of the antigen (see Prot. Sci. 9 (2000) 487-496), and cross-blocking.
[0210] The terms “antibody-dependent cell cytotoxicity,” “antibody-dependent cell-mediated cytotoxicity,” or “ADCC” refer to mechanisms that induce cell death that rely on the interaction between antibody-coated target cells and lytic effector cells (such as natural killer (NK) cells, monocytes, macrophages, and neutrophils) via Fcγ receptors (FcγR) expressed on the effector cells. For example, NK cells express FcγRIIIa, while monocytes express FcγRI, FcγRII, and FcγRIIIa. The ADCC activity of the antibodies described herein can be assessed in vitro using cells expressing the antigen as target cells and NK cells as effector cells. Cell lysis is detected based on the release of markers (e.g., radioactive substrates, fluorescent dyes, or native intracellular proteins) from lysed cells.
[0211] The term "antibody-dependent phagocytosis (ADCP)" refers to the mechanism by which antibody-coated target cells are eliminated through internalization by phagocytes (such as macrophages or dendritic cells).
[0212] The term "complement-dependent cytotoxicity" or "CDC" refers to a mechanism that induces cell death in which the Fc effector domain of a target-binding antibody binds to and activates the complement component C1q. C1q then activates the complement cascade, leading to target cell death. Activation of complement can also result in the deposition of complement components on the surface of target cells, which promote CDC by binding to complement receptors (e.g., CR3) on leukocytes.
[0213] The term "nucleic acid" is used interchangeably with the term "polynucleotide" herein and refers to deoxyribonucleotides or ribonucleotides and their polymers in single-stranded or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, or non-natural, have similar binding properties to a reference nucleic acid, and are metabolized in a manner similar to that of a reference nucleotide. Examples of such analogs include, but are not limited to, phosphate thioesters, aminophosphate esters, methylphosphonates, chiral methylphosphonates, 2-O-methylribonucleotides, and peptide-nucleic acids (PNAs).
[0214] "Separated nucleic acid" refers to a nucleic acid molecule that has been separated from its components in its natural environment. Separated nucleic acid encoding a polypeptide refers to one or more nucleic acid molecules encoding a polypeptide, including one or more such nucleic acid molecules in a single vector or separate vectors, and one or more such nucleic acid molecules present at one or more locations in the host cell. Unless otherwise stated, a specific nucleic acid sequence also implicitly encompasses variants of its conserved modifications (e.g., degenerate codon substitutions) and complementary sequences, as well as explicitly stated sequences. Specifically, as detailed below, degenerate codon substitutions can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with a mixture of bases and / or deoxyinosine residues.
[0215] The terms “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers, where one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acids, as well as to both naturally occurring and non-naturally occurring amino acid polymers. Unless otherwise stated, a particular peptide sequence also implicitly encompasses variants with conserved modifications.
[0216] The term "sequence identity" refers to the degree (percentage) to which two sequences share the same amino acids / nucleic acids at equivalent positions when optimally aligned; gaps may be introduced, where necessary, to obtain the maximum percentage of sequence identity, without considering any conserved substitutions as part of sequence identity. To determine the percentage of sequence identity, alignment can be performed using techniques known in the art, such as publicly available computer software like BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software. Those skilled in the art can determine the parameters suitable for measuring alignment, including any algorithms required to achieve maximum alignment across the full length of the sequences being compared.
[0217] The term "vector" refers to a polynucleotide molecule capable of transporting another polynucleotide linked to it. One type of vector is a "plasmid," which is a circular double-stranded DNA loop in which an additional DNA segment can be attached. Another type of vector is a viral vector, such as an adeno-associated virus vector (AAV or AAV2), in which an additional DNA segment can be attached to the viral genome. Some vectors are capable of autonomous replication in the host cells to which they are introduced (e.g., bacterial vectors with bacterial origins of replication and attachable mammalian vectors). Other vectors (e.g., non-attached mammalian vectors) can integrate into the host cell's genome after introduction into the host cell, thereby replicating along with the host genome. The term "expression vector" or "expression construct" refers to a vector capable of transforming host cells and containing a nucleic acid sequence that directs and / or controls (alongside the host cell) the expression of one or more heterologous coding regions operatively linked to it. Expression constructs can include, but are not limited to, sequences that affect or control transcription, translation, and, in the presence of introns, influence RNA splicing of coding regions operatively linked to them.
[0218] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the progeny of such cells. Host cells include “transformers” and “transformed cells,” which include primary transformed cells and their derived progeny, regardless of the number of passages. Progeny may not be identical to parental cells in their nucleic acid contents and may contain mutations. Mutant progeny are included herein, which have the same function or biological activity as cells screened or selected in the initial transformed cells. Host cells include prokaryotic and eukaryotic host cells, wherein eukaryotic host cells include, but are not limited to, mammalian cells, insect cell lines, plant cells, and fungal cells. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, cow, horse, and hamster cells, including but not limited to Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, young hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, and HEK-293 cells.Fungal cells include yeast and filamentous fungal cells, including, for example, *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia minuta* (Ogataea minuta, *Pichia lindneri*), *Pichia xiaopuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia* genus, *Saccharomyces cerevisiae*, *Saccharomyces* genus, and *Hansenula*. The following are listed: *C. polymorpha*, *Kluyveromyces lactis*, *Candida albicans*, *Aspergillus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium lucknowense*, *Fusarium sp.*, *Fusarium gramineum*, *Fusarium venenatum*, *Physcomitrella patens*, *Neurospora crassa*, and *Yarrowia lipolytica*.
[0219] The terms “cell,” “cell line,” and “cell culture” are used interchangeably, and all such names include progeny. Therefore, the terms “transformation” and “transformed cell” include primary subject cells and cultures derived from them, regardless of the number of passages. It should also be understood that due to intentional or unintentional mutations, not all progeny will have exactly the same DNA contents. This includes mutant progeny that have the same function or biological activity as the original transformed cells.
[0220] The term "alkyl" refers to a saturated, straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C2). 1-20 Alkyl group). The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C12). 1-12 Alkyl groups, more preferably alkyl groups having 1 to 6 carbon atoms (i.e., C14-C6 ... 1-6 Alkyl groups). Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their various branched isomers, etc. Alkyl groups can be substituted or unsubstituted. When substituted, they can be substituted at any usable connection point. The substituents are preferably selected from one or more of the following: D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0221] The term "alkylene" refers to a divalent alkyl group, wherein the alkyl group, as defined above, has 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C2). 1-20 Alkylenes). The alkylene group is preferably an alkylene group having 1 to 12 carbon atoms (i.e., C12). 1-12 Alkylenes, more preferably alkylenes having 1 to 6 carbon atoms (i.e., C16-164 ... 1-6Alkylenes. Non-limiting examples include: -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH2CH3)-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. Alkylenes can be substituted or unsubstituted, and when substituted, they can be substituted at any usable linking point. Substituents are preferably selected from one or more of the following: D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0222] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic carbocyclic (i.e., monocyclic cycloalkyl) or polycyclic system (i.e., polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 3 to 20 membered cycloalkyl). The cycloalkyl is preferably a monocyclic alkyl (i.e., 3 to 12 membered cycloalkyl) having 3 to 12 ring atoms, more preferably a monocyclic alkyl (i.e., 3 to 8 membered cycloalkyl) having 3 to 8 ring atoms, and most preferably a monocyclic alkyl (i.e., 3 to 6 membered cycloalkyl) having 3 to 6 ring atoms.
[0223] The term "halogenated alkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.
[0224] The term “deuterated alkyl” refers to an alkyl group that is replaced by one or more deuterium atoms, wherein the alkyl group is as defined above.
[0225] The term "hydroxyalkyl" refers to an alkyl group that is substituted with one or more hydroxyl groups, wherein the alkyl group is as defined above.
[0226] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0227] In the chemical structure of the compound disclosed herein, the bond... This indicates that the configuration is not specified; that is, if chiral isomers exist in the chemical structure, the bond... It can be Or simultaneously include Two configurations.
[0228] Antibody drug conjugates (ADCs) are antibodies linked to biologically active cytotoxins or small molecule drugs with cytotoxic activity via a linker unit.
[0229] The antibodies or antibody fragments described in this disclosure can be conjugated to effector molecules in any manner. For example, antibodies or antibody fragments can be attached to cytotoxic drugs by chemical or recombinant methods. Chemical methods for preparing fusions or conjugates are known in the art and can be used to prepare conjugates. The method used for conjugating antibodies or antibody fragments and drugs must be able to link the antibody to the cytotoxic drug without interfering with the ability of the antibody or antibody fragment to bind to the target molecule.
[0230] Drug loading, also known as drug-to-antibody ratio (DAR), is the average number of drugs conjugated to each antibody in an ADC. It can range from, for example, about 1 to about 20 drugs conjugated to each antibody, and in some embodiments, from about 1 to about 10 drugs conjugated to each antibody, and in some embodiments, from about 1 to about 8 drugs conjugated to each antibody, preferably from the ranges of 2-8, 2-7, 2-6, 2-5, 2-4, 3-4, 3-5, 5-6, 5-7, 5-8, and 6-8. Exemplarily, the drug loading can be an average of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. The general formula of the ADC disclosed herein includes a set of conjugates within the aforementioned ranges. In embodiments of the disclosure, the drug loading can be expressed as n, which can be a decimal or an integer. The drug loading can be determined using conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA assays, and HPLC.
[0231] The term "connector unit," "linker fragment," or "linker cell" refers to a chemical structural fragment or bond that is linked at one end to an antibody or its antigen-binding fragment and at the other end to a drug. It may also be linked to other connectors before being linked to a drug. The term "connector" may comprise one or more connector components. Exemplary connector components include 6-maleiminohexanoyl ("MC"), maleiminopropionyl ("MP"), valine-citrulline ("val-citrate" or "vc"), alanine-phenylalanine ("ala-phe"), and those derived from coupling with a connector reagent: N-succinimino-4-(2-pyridylthio)valerate ("SPP"), N-succinimino-4-(N-maleiminomethyl)cyclohexane-1-carboxylate ("SMCC," also referred to herein as "MCC"), and N-succinimino-(4-iodo-acetyl)aminobenzoate ("SIAB"). The linker may include extensions, spacers, and amino acid units, and may be synthesized by methods known in the art, such as those described in US2005-0238649A1. The linker may be a “cleavable linker” that facilitates drug release into cells. For example, acid-labile linkers (e.g., hydrazones), protease-sensitive linkers (e.g., peptidase-sensitive linkers), light-labile linkers, dimethyl linkers, or disulfide-containing linkers may be used.
[0232] The compounds disclosed herein, or pharmaceutically acceptable salts thereof, include solvates (e.g., hydrates, non-aqueous solvates) or non-solvents of the compounds or pharmaceutically acceptable salts thereof.
[0233] "Optional" or "optionally" means that the event or circumstances described below may, but do not have to, occur, including the circumstances in which the event or circumstances may or may not occur.
[0234] The term "pharmaceutical composition" means a mixture containing one or more antibodies, conjugates or antibody-drug conjugates described herein, and other chemical components, such as physiological / pharmaceutical carriers, diluents or excipients.
[0235] The term "pharmaceutically acceptable carrier, diluent, or excipient" refers to a component in a pharmaceutical formulation that is different from the active ingredient and is non-toxic to the subject. Pharmaceutically acceptable carriers, diluents, or excipients include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0236] The terms "subject" or "individual" include both humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals) such as non-human primates, sheep, dogs, cattle, chickens, amphibians, and reptiles. Unless otherwise specified, the terms "patient" or "subject" are used interchangeably herein. In some embodiments, the individual or subject is a human being.
[0237] "Administration" or "giving," when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refers to the contact between an exogenous drug, therapeutic agent, diagnostic agent, or composition and the animal, human, subject, cell, tissue, organ, or biological fluid.
[0238] The term "sample" refers to a collection (such as fluid, cells, or tissue) separated from a subject, as well as fluids, cells, or tissues present within a subject. Exemplary samples include biological fluids such as blood, serum and serous fluid, plasma, lymph, urine, saliva, cystic fluid, tears, excretions, sputum, mucosal secretions of secretory tissues or organs, vaginal secretions, ascites, pleura, pericardium, peritoneum, fluids in the abdominal cavity and other body cavities, fluids collected by bronchoalveolar lavage fluid, synovial fluid, liquid solutions in contact with the subject or biological sources, such as culture media (including conditioned media), lavage fluids, tissue biopsy samples, fine-needle aspiration, surgically removed tissue, organ cultures, or cell cultures.
[0239] "Treatment" and "treatment" (and their grammatical variations) refer to a clinical intervention on the individual being treated, and can be implemented for prevention or during a clinicopathological process. The expected effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing / decreasing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and resolving or improving the prognosis.
[0240] An "effective dose" is generally an amount sufficient to reduce the severity and / or frequency of symptoms, eliminate these symptoms and / or underlying causes, prevent the occurrence of symptoms and / or underlying causes, and / or improve or mitigate damage caused by or associated with a disease state (e.g., lung disease). In some implementations, an effective dose is a therapeutically effective dose or a preventatively effective dose. A "therapeuticly effective dose" is an amount sufficient to treat a disease state or symptom, especially a state or symptom associated with that disease state, or otherwise prevent, inhibit, delay, or reverse the progression of the disease state or any other undesirable symptom associated with that disease. A "preventatively effective dose" is an amount that, when given to a subject, will have a predetermined preventative effect, such as preventing or delaying the onset (or recurrence) of the disease state, or reducing the likelihood of the onset (or recurrence) of the disease state or related symptoms. Complete treatment or prevention may not occur after a single dose, but may occur after a series of doses. Therefore, a therapeutically or preventatively effective dose may be administered in a single or multiple-dose manner. "Therapeutic effective dose" and "preventive effective dose" can vary depending on a number of factors, such as an individual's disease state, age, sex, and weight, as well as the ability of the treatment or combination of treatments to elicit the desired response in the individual. Exemplary indicators of an effective treatment or combination of treatments include, for example, improved health status in the patient.
[0241] This disclosure discloses an antigen-binding molecule that specifically binds to αvβ6.
[0242] This disclosure provides antigen-binding molecules that specifically bind to αvβ6 and possess numerous advantageous properties, such as good affinity, therapeutic activity, safety, pharmacokinetic properties, and drugability (e.g., solubility, viscosity, purity, and stability).
[0243] Exemplary antigen-binding molecules that specifically bind to αvβ6
[0244] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein:
[0245] The amino acid sequences of the heavy chain variable region HCDR1 are shown in SEQ ID NO: 92, HCDR2 in SEQ ID NO: 93, and HCDR3 in SEQ ID NO: 7; the amino acid sequences of the light chain variable region LCDR1 are shown in SEQ ID NO: 94, LCDR2 in SEQ ID NO: 95, and LCDR3 in SEQ ID NO: 96, wherein:
[0246] X1YWIX2 SEQ ID NO: 92;
[0247] EILPGIGRTHYSEKFX3V SEQ ID NO: 93;
[0248] RSSX4SX5X6HX7X8X9ITYLN SEQ ID NO: 94;
[0249] X 10 VSX 11 RFS SEQ ID NO: 95;
[0250] SQX 12 THIPYT SEQ ID NO: 96;
[0251] X1 is G or V, preferably G; X2 is E or I, preferably E;
[0252] X3 can be K or Q, with K being preferred;
[0253] X4 is Q or E, preferably Q; X5 is L or V, preferably L; X6 is V or A, preferably V; X7 is S or T, preferably S; X8 is N, Q or T, preferably N; X9 is G, V or E, preferably G.
[0254] X 10 The choice is K or R, with K being preferred; X 11 It can be N or S, with N being preferred;
[0255] X 12 It can be S or T, with S being preferred.
[0256] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein:
[0257] The amino acid sequences of the heavy chain variable region HCDR1 are shown in SEQ ID NO: 5, 46 or 47, the amino acid sequences of HCDR2 are shown in SEQ ID NO: 6 or 23, and the amino acid sequences of HCDR3 are shown in SEQ ID NO: 7. The amino acid sequences of the light chain variable region LCDR1 are shown in SEQ ID NO: 8, 19, 20, 54, 55, 56, 57, 58 or 59, the amino acid sequences of LCDR2 are shown in SEQ ID NO: 21, 9 or 22, and the amino acid sequences of LCDR3 are shown in SEQ ID NO: 10 or 62.
[0258] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein:
[0259] The amino acid sequences of the heavy chain variable region HCDR1 are shown in SEQ ID NO: 5, HCDR2 in SEQ ID NO: 6, and HCDR3 in SEQ ID NO: 7. The amino acid sequences of the light chain variable region LCDR1 are shown in SEQ ID NO: 8 or 57, LCDR2 in SEQ ID NO: 9 or 21, and LCDR3 in SEQ ID NO: 10.
[0260] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein:
[0261] The amino acid sequences of the heavy chain variable region HCDR1 are shown in SEQ ID NO: 5, HCDR2 are shown in SEQ ID NO: 6, and HCDR3 are shown in SEQ ID NO: 7. The amino acid sequences of the light chain variable region LCDR1 are shown in SEQ ID NO: 8, LCDR2 are shown in SEQ ID NO: 21, and LCDR3 are shown in SEQ ID NO: 10.
[0262] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein:
[0263] The amino acid sequences of the heavy chain variable region HCDR1 are shown in SEQ ID NO: 5, HCDR2 in SEQ ID NO: 6, and HCDR3 in SEQ ID NO: 7, and the amino acid sequences of the light chain variable region LCDR1 in SEQ ID NO: 8, LCDR2 in SEQ ID NO: 9, and LCDR3 in SEQ ID NO: 10.
[0264] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein:
[0265] The amino acid sequences of the heavy chain variable region HCDR1 are shown in SEQ ID NO: 5, HCDR2 are shown in SEQ ID NO: 6, and HCDR3 are shown in SEQ ID NO: 7. The amino acid sequences of the light chain variable region LCDR1 are shown in SEQ ID NO: 57, LCDR2 are shown in SEQ ID NO: 21, and LCDR3 are shown in SEQ ID NO: 10.
[0266] For example, in the antigen-binding molecules that specifically bind to αvβ6 as disclosed above, the heavy chain variable regions HCDR1, HCDR2, and HCDR3 and the light chain variable regions LCDR1, LCDR2, and LCDR3 are defined according to the Kabat numbering rules.
[0267] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0268] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 97, HCDR2 contain the amino acid sequence of SEQ ID NO: 98, and HCDR3 contain the amino acid sequence of SEQ ID NO: 99. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 100, LCDR2 contain the amino acid sequence of SEQ ID NO: 106, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to the IMGT numbering rules.
[0269] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0270] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 102, HCDR2 contain the amino acid sequence of SEQ ID NO: 103, and HCDR3 contain the amino acid sequence of SEQ ID NO: 7. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 8, LCDR2 contain the amino acid sequence of SEQ ID NO: 21, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to Chothia numbering rules.
[0271] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0272] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 97, HCDR2 contain the amino acid sequence of SEQ ID NO: 98, and HCDR3 contain the amino acid sequence of SEQ ID NO: 99. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 100, LCDR2 contain the amino acid sequence of SEQ ID NO: 101, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to the IMGT numbering rules.
[0273] In some embodiments, an antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, wherein:
[0274] The heavy chain variable regions HCDR1 contain the amino acid sequence of SEQ ID NO: 102, HCDR2 contain the amino acid sequence of SEQ ID NO: 103, and HCDR3 contain the amino acid sequence of SEQ ID NO: 7. The light chain variable regions LCDR1 contain the amino acid sequence of SEQ ID NO: 8, LCDR2 contain the amino acid sequence of SEQ ID NO: 9, and LCDR3 contain the amino acid sequence of SEQ ID NO: 10. The heavy chain variable regions HCDR1, HCDR2, and HCDR3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are all defined according to Chothia numbering rules.
[0275] Exemplarily, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein:
[0276] The heavy chain variable regions HCDR1, HCDR2, and HCDR3 are respectively the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, and the light chain variable regions LCDR1, LCDR2, and LCDR3 are respectively the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80.
[0277] For example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein the heavy chain variable regions HCDR1, HCDR2, and HCDR3 and the light chain variable regions LCDR1, LCDR2, and LCDR3 are defined according to the numbering rules selected from Kabat, IMGT, Chothia, AbM, and Contact.
[0278] For example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein, wherein the heavy chain variable regions HCDR1, HCDR2, and HCDR3 and the light chain variable regions LCDR1, LCDR2, and LCDR3 are defined according to the Kabat numbering rules.
[0279] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0280] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 65, 24-32, 63, 64, 66 or 67, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 80, 33-41, 68-79, 81, 82 or 83.
[0281] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0282] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 65 or 30, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 80 or 38.
[0283] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0284] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 65, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 80.
[0285] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0286] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 30, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 38.
[0287] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0288] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 65, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 38.
[0289] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0290] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 30, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 80.
[0291] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0292] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 65, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 79.
[0293] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0294] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 65, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 83.
[0295] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain variable region and a light chain variable region, wherein:
[0296] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 3, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 4.
[0297] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0298] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 91, and the amino acid sequence of the light chain is shown in SEQ ID NO: 86.
[0299] By way of example, the antigen-binding molecule that specifically binds to αvβ6 disclosed herein comprises a heavy chain and a light chain, wherein:
[0300] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 90, and the amino acid sequence of the light chain is shown in SEQ ID NO: 45.
[0301] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0302] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 85, and the amino acid sequence of the light chain is shown in SEQ ID NO: 86.
[0303] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0304] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 85, and the amino acid sequence of the light chain is shown in SEQ ID NO: 87.
[0305] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0306] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 85, and the amino acid sequence of the light chain is shown in SEQ ID NO: 88.
[0307] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0308] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain is shown in SEQ ID NO: 45.
[0309] In some embodiments, the antigen-binding molecule that specifically binds to αvβ6, as described in any of the preceding embodiments, comprises a heavy chain and a light chain, wherein:
[0310] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain is shown in SEQ ID NO: 14.
[0311] The antigen-binding molecule provided in this disclosure may also contain an amino acid sequence having at least 80% (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the above-mentioned amino acid sequence, such as a CDR sequence, a variable region sequence, a heavy chain, or a light chain sequence.
[0312] Antigen-binding molecular structure
[0313] In some implementations, the antigen-binding molecule provided herein is a full-length antibody.
[0314] In some implementations, the antigen-binding molecule provided herein is an antigen-binding fragment.
[0315] In some embodiments, the antigen-binding molecule provided herein is an antibody fragment. In some embodiments, the antigen-binding fragment is a Fab, Fab′, Fab′-SH, or F(ab′)2 fragment, particularly a Fab fragment. “Fab” is a monovalent fragment consisting of VL, VH, CL, and CH1 domains. A “Fab fragment” can be generated by cleavage of an antigen-binding molecule via papain. “Fab′” contains VL, CL, VH, and CH1, and also contains a region between the CH1 and CH2 domains such that interchain disulfide bonds can form between the two heavy chains of two Fab′ fragments to form an F(ab′)2 molecule. “Fab′-SH” is a Fab′ fragment in which the cysteine residues in the constant region have free thiol groups. “F(ab′)2” is a divalent fragment comprising two Fab fragments linked by disulfide bonds in the hinge region.
[0316] In some implementations, the antigen-binding fragment is a biantibody, triantibody, or tetraantibody. A biantibody is an antibody fragment with two antigen-binding sites, containing linked VH and VL domains within the same polypeptide chain (VH-VL). By using a short linker that prevents pairing between two domains on the same chain, these domains are forced to pair with complementary domains on another chain, thereby creating two antigen-binding sites. The two antigens can be the same or different.
[0317] In some embodiments, the antigen-binding fragment is a single-chain Fab fragment. A “single-chain Fab fragment” or “scFab” is a polypeptide consisting of VH, CH1, VL, CL, and a linker, wherein the antigen-binding domain and the linker have one of the following sequences in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. In some embodiments, the linker is a polypeptide having at least 30 amino acids. In some embodiments, the linker is a polypeptide having between 32 and 50 amino acids. The single-chain Fab fragment is stabilized via a native disulfide bond between CL and CH1. Additionally, these single-chain Fab molecules can be further stabilized by inserting cysteine residues (e.g., at position 44 in the heavy chain variable region and position 100 in the light chain variable region, according to Kabat numbering) to create interchain disulfide bonds.
[0318] In some implementations, the antigen-binding fragment is an Fv fragment consisting of the VH and VL domains of a single arm of the antibody.
[0319] In some embodiments, the antigen-binding fragment is a single-chain variable fragment (scFv). An “scFv” is a fusion protein comprising at least one antigen-binding fragment containing a light chain variable region and at least one antigen-binding fragment containing a heavy chain variable region, wherein the light and heavy chain variable regions are sequentially linked by a short, flexible peptide linker, capable of being expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the intact antigen-binding molecule from which it originates. Unless otherwise specified, the scFv may have VL and VH variable regions in any order herein; for example, relative to the N-terminus and C-terminus of the polypeptide, the scFv may comprise a VL-linker-VH or may comprise a VH-linker-VL.
[0320] In some embodiments, the antigen-binding fragment is dsFv, which is obtained by linking polypeptides in which one amino acid residue in each of VH and VL is replaced by a cysteine residue via disulfide bonds between cysteine residues. The amino acid residues to be replaced by cysteine residues can be selected based on the prediction of the three-dimensional structure of the antigen-binding molecule according to known methods (Protein Engineering. 7:697 (1994)).
[0321] In some implementations, the antigen-binding fragment is a single-domain antibody (dAb). A single-domain antibody is an antibody fragment containing all or part of the heavy chain variable domain or all or part of the light chain variable domain.
[0322] In some embodiments, the antigen-binding molecules provided herein are chimeric antibodies. In some embodiments, the chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In some embodiments, the chimeric antibody is a "class-switched" antibody, wherein the class or subclass has been changed from the class or subclass of the parent antibody.
[0323] In some embodiments, the antigen-binding molecule is a humanized antibody. Typically, a non-human antibody is humanized to reduce its immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody contains one or more variable regions, wherein the CDR or a portion thereof is derived from the non-human antibody, and the FR or a portion thereof is derived from the human antibody. Optionally, the humanized antibody may also contain a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody may be replaced with corresponding residues from a non-human antibody (e.g., an antibody providing the CDR sequence).
[0324] Humanized antibodies and their generation methods are reviewed in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); US Patent Nos. 5,821,337,7,527,791,6,982,321 and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describes specificity-determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describes “resurfuacing”); Dall'Acqua et al., Methods 36:43-60 (2005) (describes “FR shuffling”); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer 83:252-260 (2000) (describes the “guided selection” method for FR shuffling).
[0325] Human frame regions that can be used for humanization include, but are not limited to: frame regions selected using a "best-fit" method (see, for example, Sims et al., J. Immunol. 151:2296 (1993)); frame regions of the common sequence of human antibodies derived from specific subgroups of light chain variable regions or heavy chain variable regions (see, for example, Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1993)); mature human (somatic mutant) frame regions or human germline frame regions (see, for example, Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and the frame regions obtained by screening FR libraries (see, for example, Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)).
[0326] Variants of antigen-binding molecules that specifically bind to αvβ6
[0327] In some embodiments, amino acid sequence variants of antigen-binding molecules that specifically bind αvβ6, as provided herein, are included. For example, improvements in binding affinity and / or other biological properties of the antigen-binding molecule may be desired. Amino acid sequence variants of the antigen-binding molecule can be prepared by introducing suitable modifications into the nucleotide sequence encoding the antigen-binding molecule, or by peptide synthesis. Such modifications include, for example, deletions, and / or insertions, and / or substitutions of residues within the amino acid sequence of the antigen-binding molecule that specifically binds αvβ6. Any combination of deletions, insertions, and substitutions may be performed to obtain the final construct, provided that the final construct possesses the desired characteristics, such as antigen-binding properties.
[0328] Replace, insert, and delete variants
[0329] In some embodiments, antigen-binding molecule variants with one or more amino acid substitutions are provided. Substitution mutagenesis sites of interest include CDR and FR. Conserved substitutions are shown in Table B under the heading “Preferred Substitutions.” More substantial variations are provided in Table B under the heading “Exemplary Substitutions” and are further described below with reference to the amino acid side chain categories. Amino acid substitutions can be introduced into the antigen-binding molecule of interest, and the product can be screened for desired activities, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0330] Table B. Substitution of Amino Acids
[0331] Based on common side-chain characteristics, amino acids can be grouped as follows:
[0332] (1) Hydrophobic: Leucine, Met, Ala, Val, Leu, Ile;
[0333] (2) Neutral and hydrophilic: Cys, Ser, Thr, Asn, Gln;
[0334] (3) Acidic: Asp, Glu;
[0335] (4) Alkaline: His, Lys, Arg;
[0336] (5) Residues that affect chain orientation: Gly, Pro;
[0337] (6) Aromatic: Trp, Tyr, Phe.
[0338] Non-conservative replacement would require replacing a member of one of these categories with a member of another category.
[0339] One class of substitution variants involves replacing one or more CDR residues in a parent antigen-binding molecule (e.g., humanized or human antibody). Generally, the resulting variants selected for further research will have alterations (e.g., improvements) to certain biological properties (e.g., increased affinity, decreased affinity, decreased immunogenicity) relative to the parent antigen-binding molecule, and / or will substantially retain some of the biological properties of the parent antigen-binding molecule. An exemplary substitution variant is an affinity-matured antigen-binding molecule, which can be conveniently generated, for example, using phage display-based affinity maturation techniques (such as those described herein). In short, one or more CDR residues are mutated, the variant antigen-binding molecule is displayed on a phage, and it is screened for specific biological activities (e.g., binding affinity). Modifications (e.g., substitutions) can be made to the CDRs, for example, to improve the affinity of the antigen-binding molecule. Such alterations can be made to CDR "hotspots"—residues encoded by codons that undergo high-frequency mutations during somatic maturation—and / or residues that come into contact with antigens, while simultaneously testing the binding affinity of the resulting variants VH or VL. In some embodiments of affinity maturation, diversity is introduced into the selected variant gene for maturation using any of a variety of methods, such as error-prone PCR, strand shuffling, or oligonucleotide-guided mutagenesis. A secondary library is then created. The library is then screened to identify any antigen-binding molecule variants with the desired affinity. Another method for introducing diversity involves CDR-directed approaches, where several CDR residues (e.g., 4-6 residues at a time) are randomized. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scan mutagenesis or modeling. In particular, HCDR3 and LCDR3 are frequently targeted.
[0340] In some embodiments, substitution, insertion, or deletion can occur within one or more CDRs, provided that such changes do not materially reduce the ability of the antigen-binding molecule to bind to the antigen. For example, conserved changes (e.g., conserved substitutions, as provided herein) can be made to the CDRs that do not materially reduce binding affinity. Such changes can, for example, be external to the antigen-contacting residues in the CDR. In some embodiments of the variant VH and VL sequences provided above, each CDR is unchanged or contains no more than one, two, or three amino acid substitutions.
[0341] One method for identifying residues or regions in an antigen-binding molecule that can serve as mutagenic targets is called "alanine scanning mutagenesis." In this method, a residue or target group of residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) is identified and replaced with a neutral or negatively charged amino acid (e.g., Ala or polyalanine) to determine whether the interaction between the antigen-binding molecule and the antigen is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. Furthermore, the contact points between the antigen-binding molecule and the antigen can be identified by studying the crystal structure of the antigen-antigen-binding molecule complex. These contact residues and adjacent residues can be targeted or eliminated as substitution candidates. Variants can be screened to determine if they contain the desired properties.
[0342] Amino acid sequence insertions include fusion of the amino and / or carboxyl ends of peptides ranging in length from 1 residue to 100 or more residues, and intra-sequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antigen-binding molecules having an N-terminal methionyl residue. Other insertion variants of antigen-binding molecules include fusions of the N- or C-terminus of an antigen-binding molecule with an enzyme or a peptide that extends the serum half-life of the antigen-binding molecule.
[0343] Recombination method
[0344] Antigen-binding molecules that specifically bind to αvβ6 can be generated using recombinant methods. For these methods, one or more isolated nucleic acids encoding antigen-binding molecules that specifically bind to αvβ6 are provided.
[0345] In some embodiments, this disclosure provides isolated nucleic acids encoding antigen-binding molecules that specifically bind αvβ6 as described above. Such nucleic acids can be derived from independent polypeptide chains encoding any of the aforementioned polypeptide chains. In some embodiments, this disclosure provides one or more vectors (e.g., expression vectors) comprising such nucleic acids. In some embodiments, this disclosure provides host cells comprising such nucleic acids. In some embodiments, a method for preparing a polypeptide or fusion protein is provided, wherein the method includes culturing host cells comprising nucleic acids encoding said polypeptide or fusion protein, as provided above, under conditions suitable for expression, and optionally recovering said antigen-binding molecules that specifically bind αvβ6 from the host cells (or host cell culture medium).
[0346] To recombinantly generate antigen-binding molecules that specifically bind to αvβ6, nucleic acids encoding the protein are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. These nucleic acids can be readily isolated and sequenced using standard procedures, or generated through recombinant methods or obtained through chemical synthesis.
[0347] Suitable host cells for cloning or expressing vectors encoding antigen-binding molecules that specifically bind to αvβ6 include prokaryotic or eukaryotic cells as described herein. For example, they can be produced in bacteria, particularly when glycosylation and Fc effector function are not required. Following expression, the expression can be separated from bacterial cell paste in a soluble fraction and further purified.
[0348] Besides prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding fusion proteins, including fungal and yeast strains. Suitable host cells for expressing fusion proteins can also be derived from multicellular organisms (invertebrates and vertebrates); examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of fall armyworm (Spodoptera frugiperda) cells; plant cell cultures can also be used as hosts, such as US5959177, US6040498, US6420548, US7125978, and US6417429; and vertebrate cells, such as mammalian cell lines adapted for growth in suspension, can also be used as hosts. Other examples of suitable mammalian host cell lines include SV40-transformed monkey kidney CV1 line (COS-7); human embryonic kidney line (293 or 293T cells); young hamster kidney cells (BHK); mouse seltoli cells (TM4 cells); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells; MRC 5 cells; and FS4 cells. Other suitable mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells; and myeloma cell lines such as Y0, NSO, and Sp2 / 0. For reviews of certain mammalian host cell lines suitable for producing antigen-binding molecules, see, for example, Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.
[0349] Measurement
[0350] The antigen-binding molecules that specifically bind to αvβ6 provided herein can be identified, screened, or characterized by their physical / chemical properties and / or biological activities using a variety of assays known in the art. In some embodiments, the activity of the antigen-binding molecules that specifically bind to αvβ6 disclosed herein is tested, for example, by known methods such as ELISA, Western blotting, etc.
[0351] Treatment methods and routes of administration
[0352] Any antigen-binding molecule that specifically binds to αvβ6 provided in this disclosure may be used for therapeutic purposes. In some embodiments, the antigen-binding molecule that specifically binds to αvβ6 provided in this disclosure is used in the manufacture or preparation of a medicament.
[0353] In some embodiments, a pharmaceutical composition comprising the antigen-binding molecule that specifically binds to αvβ6 is provided, for example, for any of the pharmaceutical uses or treatment methods described above. In some embodiments, the pharmaceutical composition comprises any antigen-binding molecule that specifically binds to αvβ6 provided herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent.
[0354] The antigen-binding molecule that specifically binds to αvβ6 disclosed herein can be used alone or in combination with other agents for treatment. For example, the antigen-binding molecule disclosed herein can be co-administered with at least one other therapeutic agent.
[0355] The antigen-binding molecules that specifically bind to αvβ6 (and any other therapeutic agents) disclosed herein may be administered by any suitable means, including parenteral, intrapulmonary, and intranasal administration, and, if local treatment is required, intralesional administration. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Administration may be carried out via any suitable route, such as by injection, such as intravenous or subcutaneous injection, depending in part on whether the administration is short-term or long-term. Various dosing schedules are considered herein, including, but not limited to, single or multiple administrations at multiple time points, bolus administration, and pulsatile infusion.
[0356] The antigen-binding molecules that specifically bind to αvβ6 disclosed herein will be formulated, administered, and applied in accordance with good medical practice. Factors considered in this context include the specific condition being treated, the specific mammal being treated, the individual patient's clinical condition, the cause of the condition, the site of delivery of the agent, the method of administration, the timing of administration, and other factors known to the medical practitioner. The antigen-binding molecules that specifically bind to αvβ6 may be formulated with or without one or more agents currently used for the prevention or treatment of the stated condition. The effective amount of such other agents depends on the amount present in the pharmaceutical composition, the type of condition or treatment, and other factors. These are generally used at the same dosage and route of administration as described herein, or at about 1% to 99% of the dosage described herein, or at other dosages, and at any route determined empirically / clinically as appropriate.
[0357] For the prevention or treatment of disease, the appropriate dosage of the antigen-binding molecule that specifically binds to αvβ6 (when used alone or in combination with one or more other additional therapeutic agents) disclosed herein will depend on the type of disease to be treated, the type of therapeutic molecule, the severity and duration of the disease, whether it is administered for prophylactic or therapeutic purposes, prior treatment, the patient's clinical history and response to the therapeutic molecule, and the judgment of the attending physician. The therapeutic molecule is appropriately administered to the patient either once or after a series of treatments.
[0358] Products
[0359] In another aspect of this disclosure, an article of manufacture is provided comprising materials that can be used to treat, prevent, and / or diagnose the aforementioned conditions. The article of manufacture comprises a container and a label or package insert on or in conjunction with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed from various materials such as glass or plastic. The container contains a composition, alone or in combination with another composition, that is effective in treating, preventing, and / or diagnosing the condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper puncturable by a hypodermic needle). At least one active agent in the composition is an antigen-binding molecule that specifically binds to αvβ6 as disclosed herein. The label or package insert indicates that the use of the composition is for the treatment of the selected condition. Furthermore, the article of manufacture may comprise: (a) a first container containing a composition comprising an antigen-binding molecule that specifically binds to αvβ6 as disclosed herein; and (b) a second container containing a composition comprising additional cytotoxic agents or other therapeutic agents. The article of manufacture in this embodiment of the present disclosure may further include a packaging insert indicating that the composition can be used to treat a specific condition. Alternatively, or additionally, the article of manufacture may further include a second (or third) container containing a pharmaceutically acceptable buffer solution. From a commercial and user perspective, it may further include other materials as desired, including other buffers, diluents, filters, needles, and syringes.
[0360] Example
[0361] The following examples and test cases further describe the invention, and these examples and test cases should not be construed as limiting the scope of the invention. The examples or test cases of the invention do not include detailed descriptions of conventional methods. Experimental methods without specific conditions are generally performed under conventional conditions, as such methods are well known to those skilled in the art and described in many publications, such as *Molecular Cloning* (Green MR, Sambrook J. *A Laboratory Manual*, 4th, 2012) published by Cold Spring Harbor Laboratory, or *Antibody Engineering: Methods and Protocols* (*Antibody Engineering: Methods and Protocols* (Humana Press, 2018) published by Springer Protocols), or according to the conditions recommended by the manufacturer of the experimental materials. Some experimental materials without a specific source are obtained commercially.
[0362] Example 1: Preparation of Antibodies
[0363] Example 1: Preparation of recombinant human αvβ6 protein for immunization
[0364] HEK293-6E cells were co-transfected with human αv(ECD)-acidic tail-his (SEQ ID NO: 1) and human β6(ECD)-basic tail-twin strep (SEQ ID NO: 2) expression vector plasmids. After 6 days, the expression supernatant was collected, diatomaceous earth was added to the culture, and the supernatant was filtered using a disposable filtration system. Purification was performed using a nickel column (Cytiva, 17371202) or Strep-Tactin XT (GE, 29401324). The nickel column was washed with PBS until the A280 reading returned to baseline, then washed with 20 mM imidazole to remove impurities, followed by elution with 300 mM imidazole. The Strep-Tactin XT was washed with PBS until the A280 reading returned to baseline, followed by elution with BXT buffer. The protein was then transferred to PBS using a concentration tube to obtain recombinant human αvβ6 protein (SEQ ID NO: 1 & SEQ ID NO: 2), which was then aliquoted for use.
[0365] The relevant protein amino acid sequences are as follows:
[0366] Human αv(ECD)-acidic tail-his amino acid sequence:
[0367] Human β6(ECD)-basic tail-twin strep amino acid sequence:
[0368] Example 2: Construction of NIH / 3T3 cell line with high β6 expression for immunization
[0369] Construction of ITGB6 (β6) viral plasmid: The ITGB6 encoding DNA sequence (GenBank: M35198.3, 17-2383) was constructed into the vector pCDH-CMV-MCS-EF1-puro to obtain the ITGB6 (β6) viral plasmid. HEK293T / 17 cells (ATCC, CRL-11268) were cultured in DMEM high-glucose medium (GE, SH30243.01) + 10% FBS (CORNING, 35-081-CV). Take an EP tube, add OPTI-MEM medium (GIBCO, 11058-021), pMD2.G plasmid (Shiyuan Bio, syb192), psPAX2 plasmid (Shiyuan Bio, syb193), ITGB6 (β6) viral plasmid and P3000 reagent (ThermoFisher, Lipofectamine TM 3000 transfection reagent, L3000008). Take another EP tube, add OPTI-MEM medium and Lipo3000 reagent (ThermoFisher, Lipofectamine TM 3000 transfection reagent, L3000008), mix well and let stand at room temperature for 5 minutes, mix the liquids from the two tubes and let stand at room temperature for 10 minutes, then add the mixture to HEK293T / 17 cells. After culturing, the supernatant is collected and filtered, after ultracentrifugation the supernatant is discarded, and DMEM high-glucose medium is added for resuspension to obtain the ITGB6 (β6) virus concentrate.
[0370] NIH / 3T3 cells (ATCC, CRL-1658) were cultured with DMEM high-glucose medium + 10% FBS, and the ITGB6 (β6) virus concentrate and polybrene (Sigma, H9268) were added. 24 hours after infection, the medium was replaced with an antibiotic-containing medium (DMEM high-glucose medium + 10% FBS + puromycin), and a NIH / 3T3 cell strain with high β6 expression was obtained after screening.
[0371] Example 3, Mouse Immunization Protocol
[0372] The anti-αvβ6 murine antibody is generated by immunizing mice. SJL / J white mice, female, 6-8 weeks old (Shanghai Slac Laboratory Animal Co., Ltd., Animal Production License No.: SCXK (Shanghai) 2022-0004) were used in the experiment. Feeding environment: SPF grade. After the mice are purchased, they are reared in the laboratory environment for 1 week, with a 12 / 12 hour light / dark cycle, a temperature of 20-25°C, and a humidity of 40-60%. The acclimatized mice were immunized according to the following protocol.
[0373] Immunization Protocol 1:
[0374] SJL / J mice were immunized subcutaneously with recombinant human αvβ6 protein (SEQ ID NO:1 & SEQ ID NO:2, constructed in Example 1). The antigens were used alternately. Gold Adjuvant (Sigma, T2684) and Thermo Immunization with Alum (Thermo, 77161) adjuvant. Antigen and adjuvant. The ratio of Gold Adjuvant was 1:1, and mice were immunized after complete emulsification; the antigen and adjuvant Thermo were used together. The ratio of alum was 3:1. After shaking and mixing, the mixture was used to immunize mice. The initial immunization dose of protein antigen was 50 μg / mouse, and subsequent routine immunizations used 25 μg / mouse / dose of protein antigen. The booster immunization dose before fusion was 50 μg / mouse / dose. Mice were immunized every two weeks. Starting from the second immunization, blood samples were collected 7-10 days after each immunization to measure the antibody titer in the mouse serum. After the 4th-5th immunization, mice with high antibody titers in their serum that were approaching a plateau were selected for spleen cell fusion. A booster immunization was performed 3 days before spleen cell fusion, via intraperitoneal injection of an antigen solution prepared from physiological saline and protein antigen.
[0375] Immunization regimen 2:
[0376] SJL / J mice were immunized with NIH / 3T3 cell line (constructed in Example 2) that highly expresses β6. The immunization route was intraperitoneal cell immunization. For mice immunized with cell antigens for the first time, prior administration of [a specific treatment / treatment] is required. Gold Adjuvant (Sigma, T2684) 0.1 mL / mouse was injected intraperitoneally, followed by intraperitoneal injection of 0.1 mL / mouse diluted with phosphate buffer half an hour later. 8 Cells were inoculated with a concentration of [value missing] mL of cell solution after being dispersed evenly. Mice were immunized every two weeks, starting with the second immunization. Blood samples were collected 7-10 days after each immunization to measure the antibody titer in the mouse serum. After the 4th-5th immunization, mice with high antibody titers in their serum that were approaching a plateau were selected, and their spleens were harvested for spleen cell fusion. A booster immunization was performed 3 days before spleen cell fusion, via intraperitoneal injection of an antigen solution prepared from physiological saline and the β6-overexpressing NIH / 3T3 cell line.
[0377] Example 4: Preparation of anti-αvβ6 monoclonal antibody
[0378] 4.1 Spleen cell fusion
[0379] The splenic lymphocytes obtained in Example 3 were fused with myeloma cells Sp2 / O-Ag14 using an optimized electrofusion method. CRL-8287 TM Hybridoma cells are obtained by fusing them together.
[0380] Based on the spleen cell count, the fused hybridoma cells were divided into 3×10⁻⁶ cells. 5 / mL-7×10 5 The culture medium (HT) was resuspended in complete medium (IMDM medium containing 20% FBS, 1×PBS, 1×HAT, and 1×OPI) at a density of 150 μL / well in a 96-well plate. After incubation at 37°C and 5% CO2 for 4-5 days, the supernatant was removed, and 200 μL / well of complete medium containing HT (IMDM medium containing 20% FBS, 1×PBS, 1×HT, and 1×OPI) was added. The plate was then incubated at 37°C and 5% CO2 for 3-4 days before detection.
[0381] 4.2 Hybridoma cell screening
[0382] Based on the hybridoma cell growth density, the hybridoma culture supernatant was analyzed using ELISA. Hybridoma cells with strong binding affinity to human αvβ6 (ACRO, IT6-H52E1) and monkey αvβ6 (ACRO, IT6-C52W9), but not binding to human αvβ1 (ACRO, IT1-H52E1), human αvβ3 (ACRO, IT3-H52E3), human αvβ5 (ACRO, IT5-H52W5), and human αvβ8 (ACRO, IT8-H52W4) were selected for timely expansion, cryopreservation, and two to three subcloning processes until a single-cell clone was obtained.
[0383] 4.3 Hybridoma antibody sequencing
[0384] The M37 monoclonal hybridoma cell line with good in vitro activity was selected, and its antibody sequence was cloned. The process was as follows: hybridoma cells in the logarithmic growth phase were collected, and RNA was extracted using Trizol reagent (Invitrogen, 15596-018) and reverse transcribed (PrimeScript). TM Reverse Transcriptase (Takara, 2680A). The cDNA obtained from reverse transcription was amplified by PCR and then sent to a sequencing company for sequencing. The antibody variable region sequence is as follows:
[0385] The variable region of the heavy chain of mouse monoclonal antibody M37 is as follows:
[0386] The variable region of the light chain of mouse monoclonal antibody M37 is as follows:
[0387] Note: The background texture is a CDR determined according to the Kabat numbering system.
[0388] Table 1-1. M37 antibody CDR sequence (Kabat numbering rules)
[0389] Table 1-2. M37 antibody CDR sequence (IMGT numbering rules)
[0390] Table 1-3. M37 antibody CDR sequence (Chothia numbering rules)
[0391] Chimeric antibodies are obtained by recombining the variable region of an antibody with the constant region of human IgG (preferably with IgG1 as the heavy chain and κ as the light chain). An example, the sequence of the chimeric antibody chM37 is shown below.
[0392] Sequences in the constant region:
[0393] Human IgG1 heavy chain constant region:
[0394] Human κ chain constant region:
[0395] The heavy chain of chM37 is as follows:
[0396] The chM37 light chain is as follows:
[0397] Note: The underlined parts in the sequence are variable regions, and the italicized parts are constant regions.
[0398] The negative control antibody hIgG1 used in this disclosure was obtained by recombination of the heavy chain variable region and light chain variable region from patent US6114143A with the human IgG constant region (heavy chain is IgG1, light chain is κ). The sequences of the heavy chain constant region and light chain constant region are SEQ ID NO: 11 and SEQ ID NO: 12, respectively, and their full-length sequences are as follows:
[0399] hIgG1 antibody heavy chain sequence:
[0400] hIgG1 antibody light chain sequence:
[0401] 4.4 Hybridoma Chimeric Antibody Expression
[0402] HEK293-6E cells were co-transfected with antibody light and heavy chain expression plasmids. After 6 days, the expression supernatant was collected, diatomaceous earth was added to the culture, and the supernatant was filtered using a disposable filtration system. The supernatant was then purified using a Protein A (Cytiva, 17543802) column. The column was washed with PBS until the A280 reading returned to baseline. The target protein was eluted with acidic elution buffer (pH 3.0-3.5) and neutralized with 1M Tris-HCl at pH 8.0-9.0. If the purity of the eluted sample was less than 95%, it was appropriately concentrated and further purified using PBS-equilibrated Superdex 200 gel chromatography (Cytiva, 90100137) or PBS-equilibrated RESOURCE S (Cytiva, 11718001) to remove aggregates and / or fragments. The monomer peaks were collected and aliquoted for later use.
[0403] Example 5: Humanization of mouse-derived anti-human αvβ6 monoclonal antibody
[0404] By comparing the mouse antibody's heavy and light chain variable region germline gene with the IMGT human antibody heavy and light chain variable region database using MOE software, germline genes with high homology to M37 were selected as templates. The CDRs of this mouse antibody were then transplanted into the corresponding human templates, forming variable region sequences in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Exemplarily, in the following specific embodiments, the CDR amino acid residues were determined and annotated using the Kabat numbering system.
[0405] The humanized antibodies for M37 were selected as the light chain framework region templates: FR1, FR2, and FR3 of IGKV2-40*01, IGKV2-28*01, or IGKV2D-29*02, and FR4 of IGKJ4*01, namely FGGGTKVEIK (SEQ ID NO:15) or FR4 of IGKJ2*01, namely FGQGTKLEIK (SEQ ID NO:16); and the heavy chain framework region templates were selected as the heavy chain framework region templates: FR1, FR2, and FR3 of IGHV1-3*01 or IGHV1-46*01, and FR4 of IGHJ6*01, namely WGQGTTVTVSS (SEQ ID NO:17) or FR4 of IGHJ4*01, namely WGQGTLVTVSS (SEQ ID NO:18). Optionally, amino acid residues at positions 2, 12, 28, 29, 45, 50, 53, 87 and / or 101 on the variable region of the light chain of the humanized antibody may be substituted; and / or amino acid residues at positions 1, 24, 28, 38, 40, 44, 64, 66, 69, 71, 75, 76, 83, 85 and / or 89 on the variable region of the heavy chain of the humanized antibody may be substituted.
[0406] Table 2. Amino acid substitutions in the variable region of M37 humanized antibody (Kabat numbering rules) Note: Q45K indicates that the 45th Q is mutated to K according to the Kabat numbering system, and so on.
[0407] Table 3. Amino acid substitutions in the variable region of M37 humanized antibody (Kabat numbering rules)
[0408] The CDR for humanized antibodies against M37 is as follows:
[0409] Table 4. CDR modification of M37 humanized antibodies (Kabat numbering rules)
[0410] The light chain variable region and heavy chain variable region sequences of the M37 humanized antibody are as follows:
[0411] >hu37VH1
[0412] >hu37VH2
[0413] >hu37VH3
[0414] >hu37VH4
[0415] >hu37VH5
[0416] >hu37VH6
[0417] >hu37VH7
[0418] >hu37VH8
[0419] >hu37VH9
[0420] >hu37VL1
[0421] >hu37VL2
[0422] >hu37VL3
[0423] >hu37VL4
[0424] >hu37VL5
[0425] >hu37VL6
[0426] >hu37VL7
[0427] >hu37VL8
[0428] >hu37VL9
[0429] Note: In the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4; the added background is the CDR determined according to the Kabat numbering system; the italicized and bolded parts are mutation sites; the rest are FR.
[0430] The heavy chain variable region and light chain variable region of the M37 humanized antibody were recombined with the human heavy chain constant region IgG1 (SEQ ID NO: 11) and the human κ chain constant region (SEQ ID NO: 12), respectively, to obtain the humanized antibody shown in Table 5 below.
[0431] Table 5. M37 Humanized Antibodies Note: In the table, "hu37H7L6" indicates that the heavy chain variable region is hu37VH7 (SEQ ID NO: 30), the light chain variable region is hu37VL6 (SEQ ID NO: 38), and the heavy chain constant region is as shown in SEQ ID NO: 11, and the light chain constant region is as shown in SEQ ID NO: 12. The humanized antibodies shown are as described above; others follow the same pattern.
[0432] For example, the full-length sequence of the hu37H1L1 humanized antibody is as follows:
[0433] hu37H1L1 antibody heavy chain sequence:
[0434] hu37H1L1 antibody light chain sequence:
[0435] For example, the full-length sequence of the hu37H7L6 humanized antibody is as follows:
[0436] hu37H7L6 antibody heavy chain sequence:
[0437] hu37H7L6 antibody light chain sequence:
[0438] Note: The underlined parts in the above sequence are variable regions, and the italicized parts are constant regions.
[0439] The light and heavy chain expression plasmids of the above antibodies were co-transfected into HEK293-6F cells. After 4 days, the expression supernatant was collected, centrifuged, and purified using Protein A (Tiandi Renhe, SA012500) magnetic beads. Finally, the target protein was eluted with acidic elution buffer at pH 3.0-3.5, neutralized with 1M Tris-HCl at pH 8.0-9.0, and aliquoted for use after concentration determination.
[0440] Example 6: CDR and FR modification of M37 humanized antibody
[0441] Point mutations were performed on the CDR or FR regions of the M37 humanized antibody. Optionally, single-point mutations were combined. Exemplarily, the following mutations were performed on hu37H7, including single-point and multi-point combination mutations, to obtain different variable regions and antibodies. In the following specific examples, the CDR amino acid residues were determined and annotated using the Kabat numbering system.
[0442] Table 6. Humanized Antibody Modification of hu37H7 (Kabat Numbering Rules)
[0443] For example, the following mutations were performed on hu37L6, including single-point and multi-point combination mutations, to obtain different variable regions and antibodies.
[0444] Table 7. Humanized Antibody Modification of hu37L6 (Kabat Numbering Rules)
[0445] The light chain variable region and heavy chain variable region sequences of the above-mentioned humanized antibody are as follows:
[0446] >hu37VH7-1
[0447] >hu37VH7-2
[0448] >hu37VH7-3
[0449] >hu37VH7-4
[0450] >hu37VH7-5
[0451] >hu37VL6-1
[0452] >hu37VL6-2
[0453] >hu37VL6-3
[0454] >hu37VL6-4
[0455] >hu37VL6-5
[0456] >hu37VL6-6
[0457] >hu37VL6-7
[0458] >hu37VL6-8
[0459] >hu37VL6-9
[0460] >hu37VL6-10
[0461] >hu37VL6-11
[0462] >hu37VL6-12
[0463] >hu37VL6-13
[0464] >hu37VL6-14
[0465] >hu37VL6-15
[0466] >hu37VL6-16
[0467] Note: In the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4; the added background is the CDR determined according to the Kabat numbering system; the italicized and bolded parts are mutation sites; the rest are FR.
[0468] The modified heavy chain variable region and light chain variable region were combined with the human heavy chain constant region IgG1 (SEQ ID NO: 11) and the human κ chain constant region (SEQ ID NO: 12) to obtain the humanized antibodies shown in Table 8 below.
[0469] Table 8. Modified antibodies against hu37H7L6
[0470] Note: In the table, "hu37H7-3L6" indicates an antibody with a heavy chain variable region of hu37VH7-3 (SEQ ID NO: 65), a light chain variable region of hu37VL6 (SEQ ID NO: 38), and a heavy chain constant region as shown in SEQ ID NO: 11 and a light chain constant region as shown in SEQ ID NO: 12. Similarly, "hu37H7-3L6-13" indicates an antibody with a heavy chain variable region of hu37VH7-3 (SEQ ID NO: 65), a light chain variable region of hu37VL6-13 (SEQ ID NO: 80), and a heavy chain constant region as shown in SEQ ID NO: 11 and a light chain constant region as shown in SEQ ID NO: 12. Other examples follow the same pattern.
[0471] For example, the full-length sequence of the hu37H7-1L6 antibody is as follows:
[0472] hu37H7-1L6 antibody heavy chain sequence:
[0473] hu37H7-1L6 antibody light chain sequence:
[0474] For example, the full-length sequence of the hu37H7-3L6 antibody is as follows:
[0475] hu37H7-3L6 antibody heavy chain sequence:
[0476] hu37H7-3L6 antibody light chain sequence:
[0477] For example, the full-length sequence of the hu37H7L6-13 antibody is as follows:
[0478] hu37H7L6-13 antibody heavy chain sequence:
[0479] hu37H7L6-13 antibody light chain sequence:
[0480] For example, the full-length sequence of the hu37H7-3L6-12 antibody is as follows:
[0481] hu37H7-3L6-12 antibody heavy chain sequence:
[0482] hu37H7-3L6-12 antibody light chain sequence:
[0483] For example, the full-length sequence of the hu37H7-3L6-13 antibody is as follows:
[0484] hu37H7-3L6-13 antibody heavy chain sequence:
[0485] hu37H7-3L6-13 antibody light chain sequence:
[0486] For example, the full-length sequence of the hu37H7-3L6-16 antibody is as follows:
[0487] hu37H7-3L6-16 antibody heavy chain sequence:
[0488] hu37H7-3L6-16 antibody light chain sequence:
[0489] Note: The underlined parts in the above sequence are variable regions, and the italicized parts are constant regions.
[0490] For example, the CDR sequence of the hu37H7-3L6-13 antibody is as follows:
[0491] Table 9-1. CDR sequence of hu37H7-3L6-13 antibody (Kabat numbering rules)
[0492] Table 9-2. CDR sequence of hu37H7-3L6-13 antibody (IMGT numbering rules)
[0493] Table 9-3. CDR sequence of antibody hu37H7-3L6-13 (Chothia numbering rules)
[0494] The light and heavy chain expression plasmids of the above antibodies were co-transfected into HEK293-6F cells. After 4 days, the expression supernatant was collected, centrifuged, and purified using Protein A (Tiandi Renhe, SA012500) magnetic beads. Finally, the target protein was eluted with acidic elution buffer at pH 3.0-3.5, neutralized with 1M Tris-HCl at pH 8.0-9.0, and aliquoted for use after concentration determination.
[0495] Example 7: Fc region mutations in hu37H7L6 and hu37H7-3L6-13 antibodies
[0496] The variable region of the hu37H7L6 or hu37H7-3L6-13 antibody is recombined with the constant region of human IgG (preferably the heavy chain is IgG1-LALA: SEQ ID NO: 89, and the light chain is κ: SEQ ID NO: 12) to obtain hu37H7L6-AA and hu37H7-3L6-13-AA antibodies. For example, the sequences of the antibodies are shown below.
[0497] Constant region sequence:
[0498] Human IgG1-LALA heavy chain constant region:
[0499] Human κ chain constant region:
[0500] The full-length sequence of the hu37H7L6-AA antibody is as follows:
[0501] hu37H7L6-AA antibody heavy chain sequence:
[0502] hu37H7L6-AA antibody light chain sequence:
[0503] The full-length sequence of the hu37H7-3L6-13-AA antibody is as follows:
[0504] hu37H7-3L6-13-AA antibody heavy chain sequence:
[0505] hu37H7-3L6-13-AA antibody light chain sequence:
[0506] The negative control antibody hIgG1-AA used in this disclosure was obtained by recombination of the heavy chain variable region and light chain variable region from patent US6114143A with the human IgG constant region (heavy chain is IgG1-LALA, light chain is κ). The sequences of the heavy chain constant region and light chain constant region are SEQ ID NO: 89 and SEQ ID NO: 12, respectively, and their full-length sequences are as follows:
[0507] hIgG1-AA antibody heavy chain sequence:
[0508] hIgG1-AA antibody light chain sequence:
[0509] Note: The underlined parts in the above sequence are variable regions, and the italicized parts are constant regions.
[0510] HEK293-6E cells were co-transfected with the light and heavy chain expression plasmids of the above antibodies. After 6 days, the expression supernatant was collected, diatomaceous earth was added to the culture, and the supernatant was filtered using a disposable filtration system. The supernatant was then purified using a Protein A (Cytiva, 17543802) column. The column was washed with PBS until the A280 reading returned to baseline. The target protein was eluted with acidic elution buffer (pH 3.0-3.5) and neutralized with 1M Tris-HCl at pH 8.0-9.0. If the purity of the eluted sample was less than 95%, it was appropriately concentrated and further purified using PBS-equilibrated Superdex 200 gel chromatography (Cytiva, 90100137) or PBS-equilibrated RESOURCE S (Cytiva, 11718001) to remove aggregates and / or fragments. The monomer peaks were collected and aliquoted for later use.
[0511] Example 2: Preparation of ADC
[0512] The following general reaction formula applies to ADC-1, ADC-2, and ADC-3, wherein compound L-1 is prepared according to Example 2-1 of patent "WO2021148003A1":
[0513] ADC-1
[0514] At 37°C, a prepared aqueous solution of tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP.HCl) (10 mM, 103.1 μL, 1031 nmol) was added to the His buffer solution of the negative control antibody hIgG1-AA (0.03 M His buffer solution at pH = 6.3; 10.0 mg / mL, 7.0 mL, 479.4 nmol). The solution was placed in a water bath and shaken at 37°C for 3 hours, after which the reaction was stopped. The reaction solution was then cooled to 25°C and adjusted to pH 5.0 using dilute acetic acid aqueous solution.
[0515] Compound L-1 (5.32 mg, 3.83 μmol) was dissolved in 380 μL of dimethyl sulfoxide and added to the above reaction solution. The mixture was placed in a constant temperature shaker and shaken at 25 °C for 3 hours, after which the reaction was stopped. The reaction solution was purified by desalting using a Sephadex G25 gel column to obtain the title product ADC-1, which was stored at 4 °C.
[0516] MS calculations showed that the average number of drugs bound per antibody molecule was n = 4.9.
[0517] ADC-2
[0518] At 37°C, a prepared aqueous solution of tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP.HCl) (10 mM, 14.3 μL, 143 nmol) was added to the His buffer solution of antibody hu37H7L6-AA (0.03 M His buffer solution at pH = 6.3; 10.0 mg / mL, 0.93 mL, 63.7 nmol). The solution was placed in a water bath and shaken at 37°C for 3 hours, after which the reaction was stopped. The reaction solution was then cooled to 25°C and adjusted to pH 5.0 using dilute acetic acid aqueous solution.
[0519] Compound L-1 (0.70 mg, 0.50 μmol) was dissolved in 48 μL of dimethyl sulfoxide and added to the above reaction solution. The mixture was placed in a constant temperature shaker and shaken at 25 °C for 3 hours, after which the reaction was stopped. The reaction solution was purified by desalting using a Sephadex G25 gel column to obtain the title product ADC-2, which was stored at 4 °C.
[0520] MS calculation of the average drug binding number per antibody molecule: n = 3.9.
[0521] ADC-3
[0522] At 37°C, a prepared aqueous solution of tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP.HCl) (10 mM, 14.1 μL, 141 nmol) was added to the His buffer solution of antibody hu37H7-3L6-13-AAAA (0.03 M His buffer solution with pH = 6.3; 10.0 mg / mL, 0.9 mL, 61.6 nmol). The solution was placed in a water bath and shaken at 37°C for 3 hours, after which the reaction was stopped. The reaction solution was then cooled to 25°C and adjusted to pH 5.0 using dilute acetic acid aqueous solution.
[0523] Compound L-1 (0.68 mg, 0.49 μmol) was dissolved in 49 μL of dimethyl sulfoxide and added to the above reaction solution. The mixture was placed in a constant temperature shaker and shaken at 25 °C for 3 hours, after which the reaction was stopped. The reaction solution was purified by desalting using a Sephadex G25 gel column to obtain the title product ADC-3, which was stored at 4 °C.
[0524] MS calculation of the average drug binding number per antibody molecule: n = 3.6.
[0525] Test case
[0526] Test Example 1: Detection of in vitro binding activity of chimeric antibodies
[0527] The monoclonal antibodies from the aforementioned examples were cloned, expressed, and purified, and affinity assays were performed using the following methods.
[0528] In 96-well microplates, 1 μg / mL of human αvβ6 (ACRO, IT6-H52E1), monkey αvβ6 (ACRO, IT6-C52W9), human αvβ1 (ACRO, IT1-H52E1), human αvβ3 (ACRO, IT3-H52E3), human αvβ5 (ACRO, IT5-H52W5), or human αvβ8 (ACRO, IT8-H52W4) were coated overnight at 4°C. Plates were washed with PBST (PBS, 0.1% Tween 20) and then blocked with PBS blocking buffer (PBS, 5% skim milk) at 37°C for 2 hours. After washing the plates, the antibodies were serially diluted with PBS binding buffer (PBS, 2% skim milk), and the diluted antibodies were added to the plates and incubated at room temperature for 2 hours. After washing the plates, Peroxidase was diluted 1:10000. F(ab')2Fragment Goat Anti-Human IgG and F(ab')2fragment specific antibody (Jackson, 109-036-097) were incubated at room temperature for 1 hour. After washing the plates, they were incubated with TMB (SeraCare, 5120-0075) substrate for 5 minutes, and the reaction was terminated with 1M H2SO4. OD450 readings were taken on a microplate reader (PE Victor 3). Data processing was performed using Graphpad Prism 10.
[0529] 1.1 The in vitro binding activity of the chimeric antibody chM37 in Example 4 was detected, and the results are shown in Table 10.
[0530] Table 10. Detection of binding between chM37 antibody and integrin protein (EC) 50 (nM))
[0531] The results showed that the chimeric antibody chM37 specifically bound to human αvβ6 (ACRO, IT6-H52E1), but not to human αvβ1 (ACRO, IT1-H52E1), human αvβ3 (ACRO, IT3-H52E3), human αvβ5 (ACRO, IT5-H52W5), or human αvβ8 (ACRO, IT8-H52W4), and also exhibited binding activity to monkey αvβ6 (ACRO, IT6-C52W9). The negative control antibody hIgG1 did not bind to integrin proteins.
[0532] 1.2 The in vitro binding activity of the humanized antibody in Example 5 to human αvβ6 protein was detected, and the results are shown in Table 11.
[0533] Table 11. Detection of binding between M37 humanized antibody and human αvβ6 protein
[0534] 1.3 The in vitro binding activity of the humanized antibody in Example 6 to human αvβ6 protein was detected, and the results are shown in Table 12.
[0535] Table 12. Detection of binding between hu37H7L6 modified antibody and human αvβ6 protein
[0536] 1.4 The in vitro binding activity of the humanized antibody in Example 6 was detected, and the results are shown in Table 13.
[0537] Table 13. Detection of binding between Hu37H7L6 modified combination antibody and integrin protein (ECG) 50 (nM))
[0538] The results showed that antibodies hu37H7-3L6-12, hu37H7-3L6-13, and hu37H7-3L6-16 specifically bound to human αvβ6 (ACRO, IT6-H52E1), but not to human αvβ1 (ACRO, IT1-H52E1), human αvβ3 (ACRO, IT3-H52E3), human αvβ5 (ACRO, IT5-H52W5), or human αvβ8 (ACRO, IT8-H52W4). Furthermore, the antibodies exhibited binding activity to monkey αvβ6 (ACRO, IT6-C52W9). The negative control antibody hIgG1 did not bind to integrin proteins.
[0539] 1.5 The in vitro binding activity of the humanized antibody in Example 7 was detected, and the results are shown in Table 14.
[0540] Table 14. Antibody-integrin protein binding detection (EC) 50 (nM))
[0541] The results showed that both hu37H7L6-AA and hu37H7-3L6-13-AA antibodies specifically bound to human αvβ6 (ACRO, IT6-H52E1), but not to human αvβ1 (ACRO, IT1-H52E1), human αvβ3 (ACRO, IT3-H52E3), human αvβ5 (ACRO, IT5-H52W5), or human αvβ8 (ACRO, IT8-H52W4). Furthermore, the antibodies exhibited binding activity to monkey αvβ6 (ACRO, IT6-C52W9). The negative control antibody hIgG1-AA did not bind to integrin protein.
[0542] Test Example 2: Antibody-Tumor Cell Binding Assay (FACS)
[0543] HCC1954 (ATCC, CRL-2338) cells were cultured in RPMI 1640 medium (Gibco, A10491-01) + 10% FBS. After digestion with trypsin (Meilun Biotechnology, PWL060), the supernatant was discarded, and the cells were resuspended in FACS buffer (PBS + 2.5% FBS + 1mM CaCl2 + 1mM MgCl2). After counting, the density was adjusted to 2E6 / mL, and 50 μL was added to each well.
[0544] The antibody to be tested was serially diluted with FACS buffer and added to the cells. After mixing, the cells were incubated on ice. After incubation, the supernatant was removed, and 100 μL of APC-anti-human FC (Biolegend, 410712) was added and mixed. The cells were incubated on ice again, and the supernatant was removed. Finally, 200 μL of FACS buffer was added to resuspend the cells, and the cells were analyzed using an Attune NxT flow cytometer. The data were analyzed and processed using FlowJO 10.
[0545] The results showed that both hu37H7L6-AA and hu37H7-3L6-13-AA antibodies could effectively bind to HCC1954 cells, while the negative control antibody hIgG1-AA did not bind to HCC1954 cells. The results are shown in Table 15.
[0546] Table 15. Detection of tumor cell binding of hu37H7L6-AA and hu37H7-3L6-13-AA antibodies.
[0547] Test Example 3: Antibody Intracellular Endocytosis Assay
[0548] HCC1954 (ATCC, CRL-2338) cells were cultured in RPMI 1640 + 10% FBS. After trypsin digestion and discarding the supernatant, the cells were counted and a cell suspension was prepared and seeded into 96-well plates with 8000 cells / 50 μL per well.
[0549] Take equal volumes of antibody and Mix Human Fabfluor-pH Red Antibody Labeling Reagent (Sartorius, 4722) thoroughly to a final antibody concentration of 80 nM. The final concentration of Human Fabfluor-pH Red Antibody Labeling Reagent was 240 nM, and it was incubated at room temperature in the dark for 35 minutes.
[0550] The above mixture was added to the cell plate and placed in an Incucyte instrument (Sartorius, Incucyte S3) for continuous real-time monitoring of fluorescence signals. The data were then exported and analyzed using a Graphpad Prism10.
[0551] The results showed that both hu37H7L6-AA and hu37H7-3L6-13-AA antibodies could be effectively internalized, while the negative control antibody hIgG1-AA could not be effectively internalized. The results are shown in Figure 1.
[0552] Test Example 4: LAP Blocking Assay with Antibody
[0553] Dilute human LAP (ACRO, LAP-H5245) to 0.3 μg / mL and coat the plate overnight. Discard the liquid, wash the plate, add PBS containing 5% BSA and let it stand at room temperature for 1 hour. Wash the plate again and set aside.
[0554] The antibody to be tested was serially diluted with PBS Dilution Buffer (1 mM CaCl2, 1 mM MgCl2, and 1% BSA). Biotin-αvβ6 (ACRO, IT6-H82E4) was diluted with PBS Dilution Buffer to a final concentration of 0.5 μg / mL. Equal volumes of the serially diluted antibody and biotin-αvβ6 were incubated at room temperature for 1 hour, and then added to LAP-coated plates and incubated at room temperature for 1 hour. HRP-conjugated streptavidin (Sangon Biotech: D111054-0001) was diluted 1:2000 with PBS Dilution Buffer and added to the washed plates, and incubated at room temperature for 1 hour.
[0555] After washing the plates, incubate with TMB (SeraCare, 5120-0075) substrate for 5 minutes, then terminate the reaction with 1M H2SO4. Read the OD450 values on a microplate reader (BMG, PHERAstar FS). Data processing was performed using a Graphpad Prism 10.
[0556] The results showed that both hu37H7L6-AA and hu37H7-3L6-13-AA antibodies had only weak LAP blocking function, comparable to the negative control antibody hIgG1-AA. The results are shown in Table 16.
[0557] Table 16. LAP blocking detection of hu37H7L6-AA and hu37H7-3L6-13-AA antibodies
[0558] Test Example 5: ADC Cell Killing Experiment
[0559] BT20 (ATCC, HTB-19) cells were cultured in EMEM medium (Meilun Biotechnology, PWL-104) + 10% FBS. After trypsin digestion, the supernatant was discarded, and the cells were resuspended in culture medium. After counting, the cell suspension was prepared and seeded into 96-well plates at 1000 cells / 135 μL per well. The cell culture plates were placed in a 5% CO2 incubator and incubated overnight at 37°C.
[0560] The ADC molecules were prepared by serial dilution, and then 15 μL of the serially diluted ADC molecules were added to each well of a cell plate. After drug addition, the plate was incubated in a 37°C incubator with 5% CO2 for 6 days.
[0561] In advance The Luminescent Cell Viability Assay (Promega, G7573) was melted and prepared in the dark. 75 μL of the prepared CTG was added to each well, and the mixture was incubated at room temperature for 10 minutes. A white sticker was then attached to the bottom of each well, and the chemiluminescence values were read using a microplate reader (PE, EnVision). The data were exported and processed using Graphpad Prism 10.
[0562] The results showed that ADC-2 and ADC-3 molecules had good inhibitory activity against tumor cell growth. The results are shown in Table 17.
[0563] Table 17. Detection of tumor cell killing effect by ADC molecules
[0564] Although the invention has been described in detail with the aid of accompanying drawings and examples for clarity of understanding, these descriptions and examples should not be construed as limiting the scope of this disclosure. All patent and scientific literature disclosures cited herein are clearly and fully incorporated by reference.
Claims
1. An antigen binding molecule that specifically binds αvβ6, comprising a heavy chain variable region and a light chain variable region, wherein, The heavy chain variable region includes HCDR1, HCDR2, and HCDR3, and the light chain variable region includes LCDR1, LCDR2, and LCDR3, wherein: The heavy chain variable region HCDR1 contains the amino acid sequence of SEQ ID NO: 92, HCDR2 contains the amino acid sequence of SEQ ID NO: 93, and HCDR3 contains the amino acid sequence of SEQ ID NO: 7, and the light chain variable region LCDR1 contains the amino acid sequence of SEQ ID NO: 94, LCDR2 contains the amino acid sequence of SEQ ID NO: 95, and LCDR3 contains the amino acid sequence of SEQ ID NO:
96.
2. An antigen binding molecule that specifically binds αvβ6, comprising a heavy chain variable region and a light chain variable region, wherein, The heavy chain variable region includes HCDR1, HCDR2, and HCDR3, and the light chain variable region includes LCDR1, LCDR2, and LCDR3, wherein: The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, 24-32, 63, 64, 66, or 67, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80, 33-41, 68-79, 81, 82, or 83; or The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO:
4. Preferably, The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, 24, 30, or 63, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80, 33, 38, 79, or 83; or The heavy chain variable regions HCDR1, HCDR2, and HCDR3 respectively contain the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, and the light chain variable regions LCDR1, LCDR2, and LCDR3 respectively contain the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO:
4. More preferably, the HCDR1, HCDR2, and HCDR3 of the heavy chain variable region comprise the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, respectively, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region comprise the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80, respectively; or the HCDR1, HCDR2, and HCDR3 of the heavy chain variable region comprise the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 30, respectively, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region comprise the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 38, respectively; or the HCDR1, HCDR2, and HCDR3 of the heavy chain variable region comprise the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 65, respectively, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region comprise the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 38, respectively; or the HCDR1, HCDR2, and HCDR3 of the heavy chain variable region comprise the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 30, respectively, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region comprise the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 80, respectively; or the HCDR1, HCDR2, and HCDR3 of the heavy chain variable region comprise the amino acid sequences of HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 3, respectively, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region comprise the amino acid sequences of LCDR1, LCDR2, and LCDR3 in SEQ ID NO: 4, respectively.
3. The antigen binding molecule specifically binding αvβ6 according to claim 1 or 2, wherein: the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, 97, 102, 46, or 47, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, 98, 103, or 23, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 7 or 99, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, 100, 19, 20, 54, 55, 56, 57, 58, or 59, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, 106, 9, 101, or 22, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 10 or 62; preferably, HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or More preferably, HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 97, HCDR2 comprises the amino acid sequence of SEQ ID NO: 98, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 99, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 100, LCDR2 comprises the amino acid sequence of SEQ ID NO: 106, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 102, HCDR2 comprises the amino acid sequence of SEQ ID NO: 103, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 9, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, LCDR2 comprises the amino acid sequence of SEQ ID NO: 9, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 97, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 98, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 99, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 100, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 101, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 102, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 103, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 9, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 62; or the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 57, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; or the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 46, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:
10.
4. The antigen binding molecule that specifically binds avb6 of any one of claims 1 to 3, wherein the antigen binding molecule that specifically binds avb6 is an antibody; Preferably, the antigen binding molecule that specifically binds avb6 is a murine, chimeric, humanized or fully human antibody; Preferably, the antigen binding molecule that specifically binds avb6 is a murine, chimeric, humanized or fully human antibody; More preferably, the antigen binding molecule that specifically binds avb6 is a humanized antibody.
5. The antigen binding molecule that specifically binds avb6 according to any one of claims 1 to 4, wherein: the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, 24-32, 63, 64, 66, or 67, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 65, 24-32, 63, 64, 66, or 67, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80, 33-41, 68-79, 81, 82, or 83, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 80, 33-41, 68-79, 81, 82, or 83; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 4; Preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, 24, 30, or 63, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 65, 30, 24, or 63, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80, 38, 79, 83, or 33, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 80, 33, 38, 79, or 83; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 4; More preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 79; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 83; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 33; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4; most preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
80.
6. The antigen binding molecule specifically binding αvβ6 according to any one of claims 1 to 5, wherein the antigen binding molecule specifically binding αvβ6 is an antigen binding fragment; Preferably, the antigen binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, Fv, scFv and dsFv.
7. The antigen binding molecule specifically binding αvβ6 according to any one of claims 1 to 5, wherein the antigen binding molecule specifically binding αvβ6 comprises a heavy chain constant region and a light chain constant region; Preferably, the heavy chain constant region is derived from a human IgGl heavy chain constant region and the light chain constant region is derived from a human kappa light chain constant region; More preferably, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 89 or 11 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:
12.
8. The antigen binding molecule specifically binding αvβ6 according to any one of claims 1 to 5, 7, wherein the antigen binding molecule specifically binding αvβ6 comprises a heavy chain and a light chain, wherein: the heavy chain comprises the amino acid sequence of SEQ ID NO: 91, 42, 44, 84, 85 or 90 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 91, 42, 44, 84, 85 or 90 and the light chain comprises the amino acid sequence of SEQ ID NO: 86, 43, 45, 87 or 88 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 86, 43, 45, 87 or 88; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 91, 42, 44, 84, 85 or 90 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 91, 42, 44, 84, 85 or 90 and the light chain comprises the amino acid sequence of SEQ ID NO: 86, 43, 45, 87 or 88 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 86, 43, 45, 87 or 88. the heavy chain comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 13 and the light chain comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 14; Preferably, the heavy chain comprises the amino acid sequence of SEQ ID NO: 91 and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 44 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 85 and the light chain comprises the amino acid sequence of SEQ ID NO: 87; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 85 and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 85 and the light chain comprises the amino acid sequence of SEQ ID NO: 88; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 90 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 42 and the light chain comprises the amino acid sequence of SEQ ID NO: 43; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 84 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 85 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 13 and the light chain comprises the amino acid sequence of SEQ ID NO: 14; More preferably, the heavy chain comprises the amino acid sequence of SEQ ID NO: 91 and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 44 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 85 and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 90 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 85 and the light chain comprises the amino acid sequence of SEQ ID NO: 45; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 44 and the light chain comprises the amino acid sequence of SEQ ID NO:
86.
9. A nucleic acid encoding the antigen binding molecule that specifically binds avb6 of any one of claims 1 to 8.
10. A host cell comprising the nucleic acid of claim 9.
11. A conjugate comprising: the antigen binding molecule that specifically binds αvβ6 of any one of claims 1 to 8 and a payload, wherein, the payload is coupled to the antigen binding molecule that specifically binds αvβ6; Preferably, the payload is selected from a cytotoxic drug.
12. A conjugate having the structure of formula Ab-L-D: wherein: Ab is an antigen binding molecule that specifically binds αvβ6, preferably an anti-αvβ6 antibody as defined in any one of claims 1 to 8; n is 1 to 20, n is a fraction or an integer; preferably n is 1 to 10, n is a fraction or an integer; more preferably n is 3 to 8, n is a fraction or an integer; - L is -L 1 - L 2 - L 3 - L 4 - the linker unit shown, wherein: L 1 -(succinimid-3-yl-N)-W 1 -(O-CR 1 R 2 -CR 3 R 4 -) q -C(O)-, wherein R 1 , R 2 , R 3 and R 4 are hydrogen atoms or C 1-6 alkyl groups; q is 0, 1, 2, 3, 4, 5 or 6; L 2 is a chemical bond; L 3 a peptide residue selected from the group consisting of one to four amino acid residues (i.e. a mono-, di-, tri- and tetrapeptide residue), wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, cysteine, valine, lysine, citrulline, serine, glutamine, glutamic acid, aspartic acid and asparagine; preferably, L 3 a dipeptide residue selected from the group consisting of VA, valine-citrulline and a tetrapeptide residue selected from the group consisting of GGFG (SEQ ID NO: 109); more preferably, L 3 a dipeptide residue selected from the group consisting of VA, valine-citrulline and a tetrapeptide residue selected from the group consisting of GGFG (SEQ ID NO: 109); more preferably, L L 4 selected from a chemical bond, -NR 5 -W 1 - and -NR 5 -W 2 -W 1 -O-C(O)-; R 5 is a hydrogen atom or C 1-6 alkyl; W 1 is -(CR 6 R 7 ) p - R 6 and R 7 are the same or different and each is independently selected from the group consisting of a hydrogen atom, a halogen, a C 1-6 alkyl group and a C 1-6 haloalkyl group, and p is 1, 2, 3, 4, 5 or 6; W 2 For phenyl, substituted phenyl or phenyl substituted phenyl; wherein L of said -L- is 1 attached to Ab, L 4 attached to drug; Preferably, L 1 -(succinimid-3-yl-N)-W 1 -(O-CH2-CH2-) q -C(O)-, q is 0, 1, 2, 3, 4, 5 or 6; L 2 is a chemical bond; L 3 is a dipeptide residue comprising valine-citrulline; L 4 -N(CH3)CH2-, -NH-CH2- or -NH-phenyl-CH2-O-C(O)-; wherein L of said -L- is 1 attached to Ab at the end 4 attached to drug.
13. The conjugate of claim 12, having a structure as shown in the general formula Ab-L-D’: wherein Ab, L and n are as defined in claim 12.
14. The coupling according to claim 12, having the following structure: wherein: n is 1 to 8, n is a fraction or an integer; preferably n is 3 to 8, n is a fraction or an integer; Ab is an antigen binding molecule that specifically binds αvβ6, comprising a heavy chain variable region and a light chain variable region, wherein the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 7, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; Preferably, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 80; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 30, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 38; More preferably, Ab is an anti-αvβ6 antibody, comprising a heavy chain and a light chain, wherein: the heavy chain comprises the amino acid sequence of SEQ ID NO: 91, and the light chain comprises the amino acid sequence of SEQ ID NO: 86; or the heavy chain comprises the amino acid sequence of SEQ ID NO: 90, and the light chain comprises the amino acid sequence of SEQ ID NO:
45.
15. The conjugate of claim 14, having the structure: ###0002### 14 15 wherein Ab and n are as defined in claim 14.
16. A pharmaceutical composition comprising an antigen binding molecule that specifically binds αvβ6 as defined in any one of claims 1 to 8 or a conjugate as defined in any one of claims 11 to 15, and one or more pharmaceutically acceptable carriers, diluents or excipients.
17. A method of treating a disease or disorder, the method comprising administering to a subject an antigen binding molecule that specifically binds αvβ6 as defined in any one of claims 1 to 8, or a conjugate as defined in any one of claims 11 to 15, or a pharmaceutical composition as defined in claim 16; Preferably, the disease or disorder is a tumor or a cancer; more preferably, the tumor or cancer is selected from the group consisting of adenocarcinoma, squamous cell carcinoma, bladder cancer, lung cancer, gastric cancer; esophageal cancer, pancreatic cancer, head and neck cancer, ovarian cancer, gastroesophageal junction cancer and cervical cancer; Most preferably, the tumor or cancer is lung cancer, head and neck cancer or esophageal cancer.
